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ABSTRACT

The worldwide HIV/AIDS pandemic has been partly controlled and treated by antivirals targeting HIV protease, integrase
and reverse transcriptase, however, drug resistance has become a serious problem. HIV-1 drug resistance to protease inhibitors
evolves by mutations in the PR gene. The resistance mutations can alter protease catalytic activity, inhibitor binding, and stability.
Different machine learning algorithms (restricted boltzmann machines, clustering, etc.) have been shown to be effective
machine learning tools for classification of genomic and resistance data. Application of restricted boltzmann machine produced
highly accurate and robust classification of HIV protease resistance. They can also be used to compare resistance profiles of
different protease inhibitors.
HIV drug resistance has also been studied by enzyme kinetics and X-ray crystallography. Triple mutant HIV-1 protease
with resistance mutations V32I, I47V and V82I has been used as a model for the active site of HIV-2 protease. The effects of four
investigational antiviral inhibitors was measured for Triple mutant. The tested compounds had significantly worse inhibition of
triple mutant with Ki values of 17-40 nM compared to 2-10 pM for wild type protease. The crystal structure of triple mutant in
complex with GRL01111 was solved and showed few changes in protease interactions with inhibitor. These new inhibitors are not
expected to be effective for HIV-2 protease or HIV-1 protease with changes V32I, I47V and V82I.
Methicillin-resistant Staphylococcus aureus (MRSA) is an opportunistic pathogen that causes hospital and communityacquired infections. Antibiotic resistance occurs because of newly acquired low-affinity penicillin-binding protein (PBP2a).
Transcriptome analysis was performed to determine how MuM (mutated PBP2 gene) responds to spermine and how Mu50 (wild
type) responds to spermine and spermine–β-lactam synergy. Exogenous spermine and oxacillin were found to alter some significant
gene expression patterns with major biochemical pathways (iron, sigB regulon) in MRSA with mutant PBP2 protein.

INDEX WORDS: HIV protease, Drug resistance, Machine learning, Restricted Boltzmann
Machine, Structure-based drug design, Staphylococcus aureus.
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1 GENERAL INTRODUCTION

Approximately 37 million people are currently infected with HIV worldwide [1].
HIV/AIDS epidemic has been partly controlled and treated by antivirals targeting different viral
proteins, including HIV protease and transcriptase [1]. HIV is a retrovirus with two types, HIV-1
and HIV-2, and HIV-1 is subdivided into groups M, N, and O. Group M is further divided into
subtypes with different geographical prevalence. The two HIV types have distinct origins. HIV-1
strains are closer to SIV that naturally infect chimpanzees (SIVcpz) [2], while HIV-2 strains are
related to SIV from sooty mangabeys (SIVsm) [3]. HIV-1 group O is the most divergent group,
and it has recently been suggested it could have originated from SIV that infected wild gorillas
(SIVgor) [4]. SIVgor is related to SIVcpz and thus it is possible that gorillas are an intermediate
reservoir of HIV-1 group O [5]. The HIV-1O epidemic pattern is restricted to the West and Central
Africa [6], Group N was only identified in 1998 [7], and its origin was traced to a recombination
event between the ancestor of group M and SIVcpz [8]. In the early 1990s the sequencing and
alignment of viral genes env and gag from different strains of HIV-1 allowed for first time to
establish the presence of well-defined HIV-1M genetic clades [9]. All HIV strains previously
classified as subtype E based on env gene phylogeny has divergent subtype A classification in gag
and pol [10]. According to the current classification, HIV-1 group M is divided into nine different
“pure” subtypes or non-recombinant forms (A-D, F-H, J and K) [11]. Genetic differences between
sub-subtypes are around 7% in pol, and to date only two subtypes are divided in sub-subtypes,
subtype A (A1 through A5) and F (F1 and F2) [12]. The remaining six HIV-1 subtypes (D, F, G,
H, J and K) represented together only 10% of new infections in 2004 [13]. HIV-1 non-B subtypes
represent a challenge to HAART treatment as there are scarce studies in the literature on the
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efficacy of treatment in the context of infection by these subtypes. Different HIV groups and
subtypes carry in their genomes genetic signatures and polymorphisms that could alter the structure
of viral proteins which are targeted by drugs, thus impairing ARV drug binding and efficacy. HIV2 is less susceptible to some PIs, such as amprenavir, ritonavir and indinavir [13]. Various HIV-1
antivirals have been developed to block several essential proteins within the viral life cycle. HIV1 protease, integrase and reverse transcriptase are successful enzyme targets in treatment of HIV1 antivirals. HIV-1 PR is crucial for the viral maturation step; it processes cleavage sites in GagPol region allowing for assembly of individual structural proteins. Some drugs block viral fusion
by blocking gp120/gp41 receptors [14], or by blocking CCR5 co-receptor [15]. Nucleoside
inhibitors (NRTI) perform chain termination [16] and non-nucleoside inhibitors (NNRTI) hinder
polymerase activity [17] targeting reverse transcriptase. HIV-1 protease inhibitors prevent
processing of Gag and Gag-Pol viral polyproteins during the virus maturation [18].

1.1. Resistance to HIV-1 PR inhibitors:

Evolution of HIV to gain resistance to anti-retroviral drugs emerges from a combination of
several factors. The factors include the high genetic diversity of the virus, lack of proof-reading
and rapid replication. The viral reverse transcriptase lacks a proofreading function and a low
fidelity transcription drives an increased rate of spontaneous mutagenesis [14]. The long term
usage of HAART (highly active antiretroviral therapy) has caused increase in the selection of
resistant strains and the virus containing resistant protease mutants is still capable of reproducing
in vivo by successful processing of the Gag and Gag-Pol precursors in the maturation stage. HIV
PR mutations are classified as either major or minor resistance mutations by their effect in HAART

3

treatment [19]. Major mutations are distributed between the active site, flap and distal regions of
the protease dimer. Several mechanisms have been described for resistance towards protease
inhibitors. Single substitutions in active site cavity residues can result in altered drug interactions,
mutations can lower dimer stability by interrupting the interactions at the interface between the
two subunits in the dimer, and distal mutations can cause low dimer stability and defects in
autoprocessing [30]. Some of the well-known single residue mutations causing resistance are
D30N, V32I, I47V, G48V, I50V, Val82 and I84V [21]. Distal major mutation of L76V is
associated with resistance to DRV, APV, IDV and LPV, while conferring susceptibility to the
other PIs. Protease with this mutation shows low dimer stability and defects in autoprocessing
[22].
Individual mutations combine to produce highly resistant virus [32]. Several multidrug and
highly resistant HIV protease mutants have been characterized to understand how the mutations
affect the structure and function of the enzyme. A D25N variant of a multidrug resistant clinical
isolate (MDR769) carries 10 mutations L10I, M36V, M46L, I54V, I62V, L63P, A71V, V82A,
I84V, and L90M and a variant of MDR769 with V82T mutation shows 11–2600-fold resistance to
all the nine available PIs [20]. A clinical isolate from a pediatric patient harboring 22 mutations in
the protease (T4S, L10V, I13A, K14R, K20I, A22V, L33I, E35D, M36I, N37D, R41K, K43S,
G48A, I54V, I66F, H69K, T74S, V82A, I84V, L89I, L90M and T91S) was studied by kinetic and
x-ray analysis in complex with DRV [23]. Some of the mutation combinations
(V82A/I84V/G48A) contribute to the collapse of the 80’s loop by directly affecting inhibitor
binding to the S1/S1′ subsites inducing long-range structural changes altering inhibitor and
substrate binding kinetics [24]. PR20, protease with 20 mutations indicates the higher dissociation
constant stemming from loss of intersubunit contacts between the more flexible flaps. Mutations
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M36I/I15V/133F in PR20 cause structural rearrangements causing flaps flexibility. Unlike other
highly resistant mutants, PR20 retains the majority of hydrogen bond interactions with clinical
inhibitors DRV, SQV and APV [25]. Different mutations in the precursor cleavage sites have been
associated with resistant protease [15]. Mutations in the gag cleavage sites of NC-p2 and p2-p6
are commonly associated with drug resistance [15].
1.2. Structure of HIV-1 PR:

It is an aspartic protease which forms dimer from identical 99-residue monomers [26]. The
dimer interface residues 1-4 from the N-terminus and 96-99 from the C-terminus glue the two
monomers [27]. Flaps are flexible and they open and close upon substrate binding, residues I50
and G51 create a transient dimer interface [28]. There are several intermolecular interactions which
occur with the movement of flaps. Water molecules play important role in the hydrolysis of
substrate; it can form a tetrahedral intermediate causing substrate hydrolysis [28]. Figure 1 shows
protease dimer showing sites of resistance mutations. Locations of resistance associated mutations
mapped on the HIV protease dimer bound with DRV (PDB: 2IEN). Major and minor mutations
are distributed among both monomers and shown in red and blue spheres, respectively [30].

Figure 1: Protease

dimer showing sites of resistance mutations. Major and minor mutations are
distributed among both monomers and shown in red and blue spheres, respectively [18].
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1.3. Action of HIV-1 PR inhibitors:

Highly active anti-retroviral (HAART) therapy consists of different inhibitors targeting
multiple life cycle of HIV virus [31]. HIV-1 protease inhibitors act by competitive inhibition. They
occupy the PR active site and inhibit proteolysis in a competitive, reversible manner. P2-P2’
positions on inhibitors fill in the S2-S2’ pockets in PR [32]. A transition state is mimicked by an
hydroxyl group between P1 and P1’ sites which displaces the active-site water nucleophile [33].
The clinical protease inhibitors used in the current setting are atazanavir, indinavir, nelfinavir,
amprenavir, darunavir, lopinavir, tipranavir and saquinavir.
1.4. Triple mutant protease with mutations V32I, I47V and V82I:

HIV-1 PR (PR1) and HIV-2 PR (PR2) share 39–48% amino acid sequence identity and the
two enzymes differ in their cleavage site sequences in the viral precursors and in their specificity
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for peptide substrates and inhibitors at the P2 positions of peptide substrates [33]. The binding site
for clinical inhibitors differs only in the conservative substitution of hydrophobic residues Val32,
Ile47, and Val82 in PR1 by Ile32, Val47, and Ile82 in PR2 [34]. Earlier studies showed that PR1
bearing the substitutions, V32I, I47V, and V82I, altered the inhibition but not the binding mode of
a tripeptide inhibitor [35]. Tie et al. have shown that the PR with three resistance mutations V32I,
I47V and V82I resembles PR2. It is poorly inhibited by amprenavir, although saquinavir and
darunavir inhibition are similar to values for wild type PR1 and PR2 [36]. Kovalevsky et al. also
proved that these three mutations in HIV-2 PR contribute fewer interactions with inhibitors relative
to HIV-1 PR [37]. The mutation I47V is located at the flaps while the mutations V32I and V82I
are away from the flaps. I47V mutation shortens the length of side chain for residue 47 while V32I
and V82I mutations increase the size of mutated side chains. The mutated side chains alter
hydrophobic interactions with inhibitors. A single substitution V82I in HIV PR-1 is associated
with resistance to ATV [19]. Therefore, it is of importance to elucidate potential mechanism of
drug resistance of three mutations V32I, I47V, and V82I toward inhibitors and testing if some
newer potent inhibitors can effectively target such mutant protease.

1.5. Investigational inhibitors designed to target resistant HIV-1:

GRL01111, GRL0519, GRL0739 and GRL0249 are very potent HIV-1 protease inhibitors
developed by structure-guided designs. GRL01111 has an improved backbone ligand-binding site
interactions with incorporation of basic-amines at the C4 position of the bis-tetrahydrofuran (bisTHF) ring. This incorporation causes a unique hydrogen bonding interactions with the backbone
carbonyl group of Gly48 as well as with the backbone NH of Gly48 in the flap region of the
enzyme active site [39]. These ligand-binding site interactions are possibly responsible for their
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potent activity. Furthermore, this inhibitor has displayed very potent enzyme inhibitory and
antiviral activity [39]. GRL0519 is a novel nonpeptidic human immunodeficiency virus type 1
(HIV-1) protease inhibitor (PI) containing tris-tetrahydrofuranylurethane (tris-THF) and a
sulfonamide isostere, is highly potent against laboratory HIV-1 strains and primary clinical
isolates. GRL-0519 blocked the infectivity and replication of HIV-1NL4-3 variants selected by up
to a 5 μM concentration of ritonavir, lopinavir, or atazanavir [40]. GRL-0519 is also potent against
multi-PI-resistant clinical HIV-1 variants isolated from patients who no longer responded to
existing antiviral regimens after long-term antiretroviral therapy, highly darunavir (DRV)-resistant
variants [40]. Furthermore, the development of resistance against GRL-0519 is substantially
delayed compared to other PIs like amprenavir (APV) and DRV. This PI has a tris-THF moiety,
compared to the bis-THF moiety present in DRV, has greater water-mediated polar interactions
with key active-site residues of protease and the tris-THF moiety and paramethoxy group
effectively fill the S2 and S2′ binding pockets [40]. GRL-0739, a novel nonpeptidic HIV-1
protease inhibitor containing a tricycle (cyclohexyl-bis-tetrahydrofuranylurethane [THF]) and a
sulfonamide isostere, is highly active against laboratory HIV-1 strains and primary clinical isolates
with minimal cytotoxicity [41]. GRL-0739 is highly active against multidrug-resistant clinical
HIV-1 variants isolated from patients who no longer responded to existing antiviral regimens after
long-term antiretroviral therapy [41]. GRL-0739 has also been showed to have a desirable central
nervous system (CNS) penetration property, as assessed using a novel in vitro blood-brain barrier
model [41]. The tricyclic ring and methoxybenzene of GRL-0739 have a larger surface and make
greater van der Waals contacts with protease than in the case of darunavir. GRL0249 is a novel
C3-substituted cyclopentyltetrahydrofuranyl (Cp-THF)-derived HIV-1 protease inhibitor [42].
The C3-functional groups on the Cp-THF ligand maximize the ligand-binding site interactions in
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the flap region of the protease [42]. It has displayed the most potent enzyme inhibitory and antiviral
activity against a panel of multidrug resistant HIV-1 variants [42].
Specific aim 3 focuses on drug resistance in triple mutant protease to understand if it can
be attenuated by formation of new interactions with inhibitors GRL01111 [39], GRL0519 [40],
GRL0739 [41] and GRL0249 [42]. We hypothesize that these newer inhibitors will have
increased interactions and improved inhibition towards the mutant HIV-1 protease relative to
established clinical inhibitors like Lopinavir (LPV) or Darunavir (DRV). Enzyme kinetics were
performed for each of the inhibitors with triple mutant to assess the effect relative to Ki values of
wild type PR. Furthermore, crystal structure of triple mutant in complex with GRL01111 was
solved for comparison with PRWT complex with the same inhibitor.
1.6. Machine learning for prediction of resistance:

Presence of specific mutations in the viral genome can be used to predict drug resistance.
Several genotype interpretation algorithms have been utilized for predicting drug resistance. These
algorithms either use a Genetics/Bayer Diagnostics genotype interpretation rules [43] to generate
the susceptibility of the infecting virus for each drug or apply a score or 'penalty' for each drug
such as the algorithm used in Stanford HIV database [44, 45]. Although these methods are fast,
they suffer from the major disadvantage of relying on specific known mutations strongly
associated with resistance and cannot identify newly appearing resistance mutations. Linear
protein sequence based methods omitting potentially valuable information from the threedimensional protein structure have also been applied in resistance classification. Statistical
methods such as cluster analysis and linear discriminant analysis have been evaluated [47], and
non-parametric methods have been proposed for high dimensionality data [48]. Several machine
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learning algorithms like linear regression, decision trees, neural networks, support vector
regression, and bayesian networks have been utilized to predict resistance. The KNN algorithm is
a non-parametric method that uses the full training data set finding the K nearest neighbors to a
query point and reports their class by majority vote. KNN in training stage is faster and it uses the
complete training data in the prediction stage. Another important algorithm is random forest (RF)
[47]. The RF algorithm is an ensemble based classifier that works with multiple decision trees to
improve the accuracy. Previous studies from our lab have predicted phenotypic results successfully
from protease sequences by applying a unified encoding of sequence and protein structure as a
feature vector [46]. Yu, et. al. (2014) have utilized support vector machines for classification of
resistance mutations [46]. This classification shows high accuracy, sensitivity and specificity for
all inhibitors. For PIs the accuracy values range from a low of 0.93 to a high of 0.96, while
sensitivity and specificity range from 0.92-0.96 and 0.94-0.98, respectively. The same technique
was applied with Artificial Neural Networks (ANN) to classify genotype-phenotype data for
resistance and the values calculated for accuracy, sensitivity and specificity for resistance to PIs
have a low of 0.91 and reach 0.97 [46]. Significantly higher accuracies have been achieved with
this technique. This approach utilizes sequences from publicly available high quality filtered
datasets obtained from the Stanford HIV drug resistance database, which includes the results of
drug

susceptibility

tests

using

the

PhenoSense

assay

(http://hivdb.stanford.edu/pages/genopheno.dataset.html). Eight protease inhibitors, atazanavir
(ATV), indinavir (IDV), nelfinavir (NFV), amprenavir (APV), darunavir (DRV), lopinavir(LPV),
tipranavir (TPV) and saquinavir (SQV), are included in the datasets.
One approach developed in our laboratory to select a small number of meaningful mutants
uses the Mean shift clustering seeking the mode of a density function in the given sample set [65].
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By clarifying the relationship between mean shift and the optimization, the algorithm could
potentially be applied on clustering and global optimization problems by declaring each mode as
representative of one cluster and assigning each data point to the mode it converges to. A nonparametric iterative mean shift with protein encoding method to extract the most representative
drug resistant mutants from the Stanford HIV database has been proven successful in identifying
representative drug resistant mutants in HIV-1 protease [67, 68]. This selection algorithm works
well on selecting drug resistant mutants from both HIV PR and RT inhibitor genotype/phenotype
data. Among all the mutants, around 250 most representative mutants were selected for different
drugs. Such selection was based on the kernel bandwidth, and the goal correlation (R2) value.
After selection, the multiple linear regression was applied on the selected mutants drug resistance
values [65]. Identifying a small number of representative mutants will enable laboratory studies of
the molecular mechanisms of resistance. In another study, RF algorithm prediction accuracies were
examined by five-fold cross-validation on the genotype-phenotype datasets [69]. A supervised
machine learning approach for automatic prediction of drug resistance was developed to handle
genotype-phenotype datasets of HIV protease (PR) and reverse transcriptase (RT). It predicts the
drug resistance phenotype and its relative severity from a query sequence. The accuracy of the
classification was higher than 0.973 for eight PR inhibitors and 0.986 for ten RT inhibitors,
respectively. The overall cross-validated regression R2-values for the severity of drug resistance
were 0.772–0.953 for 8 PR inhibitors and 0.773–0.995 for 10 RT inhibitors [69].
1.7. Delaunay triangulation:

As mentioned in section 1.6, each of the machine learning approaches like mean shift
clustering or RF utilizes our efficient in-house sequence-structure encoding technique with
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Delaunay triangulation (DT) [46, 65, 67, 69]. DT is a triangulation such that the circumsphere of
every d-simplex is empty. It does not contain any of the given points in its interior. DT minimizes
the maximum radius of circle and it maximizes the minimum angle. Distance along edges from
DT between two vertices is constant time the Euclidean distance between them. There are several
algorithms for calculating DT: local improvement, starting with an arbitrary triangulation,
algorithm locally flips the faces of pairs of adjacent simplices according to the circumsphere
criteria. Incremental construction, DT constructed by successively building simplices whose
circumspheres contain no points in P (first point selection is usually a middle point). Incremental
insertion, recursively adding and testing by putting points from P at one time in a triangulation
(order of adding is not important). Higher dimensional embedding by applying convex hull
(smallest convex set that contains X). Divide and conquer, recursive partitioning and local
triangulation of point sets. Euclidean distance or Euclidean metric is the straight-line distance
between two points in Euclidean space. In three-dimensional Euclidean space, the distance is:

In MATHLAB ‘delaunayn’ function can make DT graphs. T = Delaunayn(X) computes a
set of simplices such that no data points of X are contained in any circumspheres of the simplices.
The set of simplices forms the Delaunay triangulation. X is an m-by-n array representing m points
in n-dimensional space. T is an array where each row contains the indices into X of the vertices of
the corresponding simplex.
1.8. Clustering algorithms:
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As stated in section 1.6, the mean shift algorithm (Fukunaga and Hostetler 1975; Cheng
1995) is a recursive algorithm that allows us to perform non-parametric mode-based clustering,
i.e. clustering data on the basis of a kernel density and has been successfully used to predict
sequences with high level resistance [65]. Agniswamy et al 2016 have successfully reported
structural analysis of HIV protease variant PRS17 selected by this technique. Other different
techniques of cluster analysis which can be applied to improve the existent analysis are KNN: an
algorithm which determines the classification of a point, combines the classification of the K
nearest points, Agglomerative hierarchical clustering: Hierarchical clustering by starting with each
point as a singleton cluster and repeatedly merging two clusters until a single, DBSCAN: Density
based clustering algorithm that produces a portioning cluster in which number of clusters is
determined by a density algorithm. It becomes a challenging task to identify certain important,
representative HIV-1 PR sequences from a pool of several hundred sequences. This paper attempts
to answer this question by implying some supervised and unsupervised machine learning
techniques. Support vector machine (SVM) and random decision forest (RF) are supervised
machine learning techniques, while K means, hierarchical agglomerative and divisive clustering
are categorized as unsupervised machine learning techniques, and we have implemented them to
identify important PR sequences from a large pool of mutants. While some groups have tried to
provide valuable insights into characterization of novel HIV drug resistance mutants using
clustering, multidimensional scaling and SVM based feature ranking from relational clinical
databases, ours attempts to select resistant sequences from existing pool.
1.9. Transcriptomic analysis of Methicillin-resistant Staphylococcus aureus (MRSA):
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MRSA is a rapidly emerging Staphylococcal infection which has developed resistance to
most of the β-lactam antibiotics causing it difficult to treat [49]. Staphylococcus aureus is a grampositive, round-shaped bacterium that is a member of the Firmicutes, and it is a usual member of
the microbiota of the body, frequently found in the upper respiratory tract and on the skin [50].
Staphylococcus aureus is both a commensal bacterium and a human pathogen. Approximately
30% of the human population is colonized with S. aureus [51]. It is a leading cause of bacteremia
and infective endocarditis (IE) as well as osteoarticular, skin and soft tissue, pleuropulmonary, and
device-related infections. While overall rates of Staphylococcus aureus may have stabilized over
the past 20 years, the contribution of methicillin-resistant S. aureus (MRSA) has fluctuated. In
Quebec, Canada, the incidence of MRSA bacteremia increased from 0 per 100,000 person-years
to 7.4 per 100,000 person-years from 1991 to 2005 [52]. Similar trends of increasing MRSA
bacteremia incidence over this time period were seen in Minnesota from 1998 to 2005 [53],
Calgary, Canada, from 2000 to 2006 and Oxfordshire, United Kingdom, from 1997 to 2003 [53].
In North America, epidemic community-associated clones of MRSA (e.g., USA300) have been
largely responsible for the increase in the incidence of MRSA bacteremia while in the United
Kingdom, epidemic health care-associated clones of MRSA [53]. Methicillin-resistant
Staphylococcus aureus (MRSA) is an opportunistic pathogen that causes hospital and communityacquired infections varying from mild skin lesions to severe, life-threatening conditions like
pneumonia, sepsis, and endocarditis [54]. The resistance occurs because of newly acquired lowaffinity penicillin-binding protein (PBP2a), which can build the cell wall when other PBPs are
blocked by beta-lactams [55]. Beta-lactam antibiotics irreversibly occupy the serine residue at the
active site of penicillin-binding proteins (PBPs) forming a stable ester-linked acyl-enzyme which
inhibits the transpeptidation process necessary for cell wall cross-linking [56]. Thus, MRSA seems
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to regulate a complex gene expression profiling when challenged with beta-lactams. Many studies
have shown that exogenous spermine may become toxic to Staphylococcus aureus [57].
Exogenous spermine exerts a dose-dependent inhibition effect on the growth of E. coli, Salmonella
enterica serovar, and Staphylococcus aureus. In Staphylococcus aureus, there are four native PBPs
(PBP1-4) and one acquired PBP2a is attributive to MRSA [58]. Recently, it was reported that
exogenous spermine may affect cell wall synthesis through its interactions with PBP2 and/or
PBP2-associated multienzyme machineries to enhance the killing effects of β-lactam antibiotics
[59]. Here an unusual finding of down regulation in sigB regulon and most ATP-producing
pathways to high dose spermine stress was reported. Exogenous spermine exerts a dose-dependent
inhibition effect on the growth of E. coli, Salmonella enterica serovar and Staphylococcus aureus
[60]. PBP2 itself or enzymatic activities associated with the PBP2-dependent complex in cell wall
synthesis could be potential target of spermine so we sought to identify a spontaneous mutation
derived MRSA strain (MuM) conferring spermine resistance and studying how this mutation can
contribute to resistance. Vancomycin works by binding to the D-Ala-D-Ala moiety, and
subsequently blocking cross-linkage of the murein monomers during the transpeptidation reactions
by PBPs [61]. We also made an intriguing finding where MuM lost spermine–β-lactam synergy
and instead gained a spermine-vancomycin synergy. Transcriptome of how MuM responds to
spermine and how Mu50 responds to spermine and spermine–β-lactam synergy is still unknown,
therefore in this aim we have systematically compared Mu50 (wild type) and MuM response to
spermine alone (high dose) or in combination with b-lactam (oxacillin) (both at low dosages) using
bioinformatics tools. We hypothesize that exogenous spermine and oxacillin can alter some
significant gene expression patterns with major biochemical pathways in Staphylococcus aureus
with mutant PBP2 protein.
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Specific Aim 1: Analysis of drug resistance in HIV protease with Restricted Boltzmann machine.
Specific Aim 2: Computational optimization of previously defined graph based sequence structure
resistance prediction technique.
Specific Aim 3: Investigating effectiveness of newer protease inhibitors against HIV-1 triple
mutant.
Specific Aim 4: To analyze biological pathways in Staphylococcus aureus with mutant penicillin
binding protein 2 on spermine and oxacillin stress.
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2 ANALYSIS OF DRUG RESISTANCE IN HIV PROTEASE

Pawar S, Freas C, Weber I, Harrison R. (2018) Analysis of drug resistance in HIV protease.
BMC Bioinformatics, 19(l11):362.

Abstract

Background: Drug resistance in HIV is the major problem limiting effective antiviral therapy.
Computational techniques for predicting drug resistance profiles from genomic data can accelerate
the appropriate choice of therapy. These techniques can also be used to select protease mutants for
experimental studies of resistance and there by assist in the development to next-generation
therapies.
Results: The machine learning produced highly accurate and robust classification of HIV protease
resistance. Genotype data were mapped to the enzyme structure and encoded using Delaunay
triangulation. Generative machine learning models trained on one inhibitor could classify
resistance from other inhibitors with varying levels of accuracy. Generally, the accuracy was best
when the inhibitors were chemically similar.
Conclusions: Restricted Boltzmann Machines are an effective machine learning tool for
classification of genomic and structural data. They can also be used to compare resistance profiles
of different protease inhibitors.
2.1 INTRODUCTION
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Human Immunodeficiency Virus (HIV) is a major pandemic disease [62]. More than 36
million people have been infected and about half of these people receive anti-retroviral therapy
[63]. However, retroviruses like HIV mutate rapidly since the conversion from the RNA genome
to DNA is error-prone [64]. They readily form quasi-species and distinct viral strains. Therefore,
retroviruses can respond effectively to selective pressures such as drug treatment by mutating to
evade the antiviral drug. The development of drug resistance in HIV is an ongoing threat to
effective long-term therapy.
Machine learning can predict drug resistance from sequence data with high accuracy as
shown by tests on genotype-resistance data for HIV protease and reverse transcriptase [65–72].
The critical improvement in the application of machine learning to drug resistance is the inclusion
of structural data in the features. We found that using Delaunay triangulation to encode the protein
structure [73] is highly effective. The encoding compresses a protein sequence and its
corresponding structure into a feature set consisting of 210 components. The set contains the
relative frequencies of each kind of amino acid pair from the structure. Yu’s use of compressed
encoding in [65] suggested that even fewer features were necessary to encapsulate drug resistance.
Therefore, we used Principle Components Analysis (PCA) to explore the remaining redundancy
in the data. The availability of a large amount of sequence and resistance data for HIV protease
(PR) has proved valuable for method development.
The validity of this approach was verified by experimental studies [74, 75]. Machine
learning was used to rigorously select representative highly resistant PR sequences for biochemical
and structural characterization. The computationally selected mutant demonstrated several orders
of magnitude worse affinity for inhibitors compared to wild type enzyme. The selected mutant had
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only one mutation in the inhibitor binding site. Therefore, a high level of resistance was achieved
almost exclusively by mutations distal from the active site.
Restricted Boltzmann Machines (RBMs) are a generative machine learning algorithm [76,
77]. RBMs only require positive, or in-class, training data, and often generalize more accurately
than other approaches. Training the standard algorithm on large datasets is often computationally
infeasible. We have developed a highly efficient version of this algorithm [78, 79]. Using a
simplified representation of the hidden and visible spins and replacing a numerical estimate of the
gradient with an analytic form results in an algorithm that is at least 14 times faster than the
conventional algorithm without compromising the accuracy.
Generative machine learning has not been applied to drug resistance in HIV. Therefore,
application of this approach to the analysis of drug resistance is of interest. This paper shows that
RBMs are as accurate as other machine learning approaches for these data. Additionally, we
studied how well RBMs trained on one drug were able to predict resistance for a different drug.
2.2 METHODS

2.2.1. Datasets and data preparation

Datasets used for the study: The genotype-phenotype datasets were downloaded from the
Stanford HIV drug resistance database [80]. Data were used for the HIV protease inhibitors:
atazanavir (ATV), nelfinavir (NFV), ritonavir (RTV), indinavir (IDV), lopinavir (LPV), tipranvir
(TPV), saquinavir (SQV), fosamprenavir (FPV) and darunavir (DRV). All the datasets were preprocessed using the methods and the cutoff values described previously in [65]. The threshold for
resistance recommended by the database curators was used in this work [80]. The results of the
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expansion of data for each of the HIV-1 PR inhibitors and proportion of resistant mutants are
shown in Table 1.
Table 1The results of the expansion for each of the HIV-1 PR inhibitors

Inhibitor

No.
isolates

No.
sequences

No.
resistant

No.
sensitive

Fraction
resistant

SQV

1722

10258

4206

6052

41.0

DRV

607

5973

1889

4084

31.6

LPV

1444

10239

5095

5144

49.8

NFV

1771

10911

6170

4741

56.5

IDV

1730

10537

5122

5415

48.6

ATV

1141

8430

4237

4193

50.3

FPV

1681

10521

4405

6116

41.9

TPV

847

7363

2062

5301

28.0

2.2.2. Pre-processing/expansion of the datasets

Wild type HIV PR has a protein sequence of 99 amino acids. Sequences with insertions,
deletions, or stop codons were removed. Genomic datasets often include multiple mutations at the
same site. In these cases, the data were expanded to multiple sequences with single amino acids at
each location to represent a single amino acid sequence for each mutant protein. For example, if
one 99-amino acid mutant sequence has two different types of amino acids at one position and
another site has three, this one sequence needs to be represented by six unique sequences each
differing in only one amino acid substitution. The pre-processing method has been explained in
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detail in [65]. Each sequence was accompanied by its inhibitor resistance fold values. The relative
resistant fold values for each of the inhibitors ranged from 0 to 800-fold resistance. Finally, the
expanded datasets with sequences were allotted a unique identifier number to help recover the
original sequences and their respective resistance fold change after analysis.
2.2.3. Encoding structure and sequence with Delaunay triangulation

A graph-based encoding system was utilized to represent the sequence and structural
information of the protein [67]. The X-ray crystal structure for HIV-1 PR (3OXC) [58] was used
as a template for creating the Delaunay triangulation. The structurally adjacent pairs of amino acids
were represented as a vector of the 210 unique pairs of 20 standard amino acids. This graph-based
encoding of sequence and structure has been proven to be a promising technique for fast and
accurate predictions of resistance from sequence in HIV infections [46, 66].
2.3.4. Principal component analysis

Principal Component Analysis (PCA) using Singular Value Decomposition (SVD) was run
on all the HIV-1 PR datasets using the Scikit-Learn machine learning library [82]. The datasets for
each inhibitor were analyzed using the Pandas data analysis library [83]. The resistance fold values
were not included in the PCA calculations since predicting these values is the goal of this work.
The results of this analysis are detailed in the “Results” section.
2.3.5. Training the RBM

The mutants with relative resistant fold less than 3.0 were classified as non-resistant
(susceptible) and denoted as 0; while those with relative resistant fold of greater than 3.0 were
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classified as resistant and denoted as 1, as used in [65] and consistent with other analyses of the
Stanford HIV resistance database [80]. RBMs work best with bit patterns. These bit patterns were
generated by scaling and dividing the range of individual features into equal intervals. Each feature
of the data was scaled to the range 0 to 1 based on the maximum and minimum values of that
feature. The scaled data were divided into eight intervals encoded with three bits per feature. The
testing and training sets were scaled independently.
The RBM was trained using gradient descent with the derivative as shown in Eq. 1. The
analytic expression for the expected value of the derivative, shown in Eq. 2 and derived in [78],
was used.
dU/dWi,j = HjVi− < dU/dWi,j > (1)
< dU/dWi,j >= Hj eβU − e−βU / eβU + e−βU (2)
In these equations, H and V are hidden and visible (or input) layers respectively, β is the
inverse temperature, U is the potential energy, and W are the weights used to define the potential.
During training, the layer that gave the best fit for each new data point was updated with a
descent step and the other layers were “anti-trained” with a small ascent step. “Anti-training”
improves the convergence and training efficiency of the RBM. Anti-training is only feasible when
using an analytic expression for the training gradient. An RBM with 150 units in the hidden layer
was trained for each category with a constant step-size of 0.1. A step-size of 0.01 was used for
anti-training. An RBM was trained for both resistant and non-resistant classes. Class membership
was assigned by the fractional reconstruction error, shown in Eq. 3 as defined in [78].
R = Hi j Wi,jVj / |Hi| j Wi,j Cj where C is the perfect reconstruction. (3)
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Five-fold cross validation was used to ensure that the results reflect the error in the models.
The models for each fold were trained to convergence with ten iterations and the values for
accuracy, positive predictive value, recall, and F from the last iteration were reported.
2.3 RESULTS

2.3.1

Classification with an RBM

The classification results are detailed in Table 2 and show a high degree of accuracy.

Table 2 The accuracy of the machine learning model

Inhibitor

Accuracy

PPV

Recall

F

Idv

0.979

0.974

0.985

0.979

Lpv

0.984

0.977

0.992

0.984

Sqv

0.969

0.963

0.986

0.974

Tpv

0.987

0.984

0.998

0.991

Drv

0.988

0.985

0.998

0.992

Atv

0.983

0.976

0.989

0.983

Nfv

0.978

0.974

0.975

0.975

Fpv

0.988

0.984

0.998

0.991
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The nearly uniform values of close to 1.0 for accuracy, PPV, recall, and F-score, show that the
models reliably predict both resistant and nonresistant classes. These results compare favorably
with our earlier results using non-generative machine learning algorithms [65–67, 69].
2.3.2

Cross-classification with an RBM

RBMs differ from non-generative machine learning methods in an interesting way. It is
trivial to train an RBM against one dataset and use it to predict the behavior of another. Table 3
shows the results of a cross-training analysis of resistance data.
Table 3Cross training reveals similarity between the inhibitors

Compound
Atv
Drv
Fpv
Idv
Lpv
Nfv
Sqv
Tpv

Atv
0.990
0.767
0.929
0.945
0.939
0.923
0.898
0.723

Drv
0.868
0.996
0.873
0.863
0.892
0.853
0.837
0.929

Fpv
0.880
0.818
0.981
0.880
0.877
0.824
0.825
0.765

Idv
0.955
0.786
0.889
0.989
0.963
0.918
0.890
0.729

Lpv
0.946
0.785
0.886
0.960
0.988
0.901
0.871
0.728

Nfv
0.914
0.718
0.822
0.905
0.891
0.987
0.840
0.655

Sqv
0.893
0.792
0.822
0.878
0.865
0.837
0.983
0.732

Tpv
0.819
0.925
0.828
0.809
0.837
0.758
0.807
0.993

Each row was trained on one inhibitor and the columns show the accuracy with which that model
predicts the resistance for the other inhibitors. The inhibitors generally, but not completely, crossclassify with high accuracy. TPV and DRV seem to have more differences from the other
inhibitors. The ability of an RBM trained on resistance to one inhibitor to predict the behavior of
resistance to another inhibitor shows that the drug resistance of HIV protease does not fully depend
on the type of drug. The existence of cross-resistance is well known and our lab has used similar
approaches to identify interesting multi-drug resistant mutants for structural study [69, 74, 75].
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2.3.3

Principal component analysis

Figure 2 shows the explained variance for each of the datasets as a function of the number
of reduced dimensions. As shown in the figure, there is overlap between some of the datasets (some
of the plots depict the same data). This suggests that redundancy exists between datasets and not
just within a single dataset. The horizontal line in the figure depicts where at least 95% of the
explained variance of the datasets is captured. In most cases, the first principal component
explained at least 90% of the observed variance. This was true for the ATV, LPV, NFV, and SQV
inhibitors. The remaining four inhibitors had an explained variance ratio between 51% and 87%
for the first principal component. For all inhibitors except for DRV, 95% of the explained variance
for each dataset was captured within 60 dimensions, suggesting that the data could be further
compressed while still minimizing the reconstruction error. For DRV, the explained variance could
be reduced to 50 dimensions. These results indicate that a more compact encoding for the
resistance data exists, consistent with Yu’s results on effectiveness of compressed encoding for
machine learning [65].
2.4 DISCUSSION

2.4.1. Classification of resistant mutations of HIV PR

The combination of structure-based encoding and RBMs is an effective technique for the
prediction of drug resistance in HIV PR. The five-fold cross validated results in Table 2 clearly
demonstrate their success and accuracy. The high values for PPV indicate that the models could
be clinically valuable. The use of an RBM is especially interesting because there are essentially no
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adjustable parameters in the process. Efficient training algorithms allow the RBM to handle large
datasets in reasonable times. While these datasets are not quite big data, they are too big for other
machine learning programs [68, 84].
2.4.2. Comparison with other methods

We pioneered the approach of using a unified representation of sequence with 3D structural
data expressed as a 210-long feature vector for

Figure 2 Principal Component Analysis on the HIV-1 PR Datasets. The similarity in the
curves indicates that the datasets have a similar underlying structure

machine learning [65]. This approach gave improved accuracy for predicting drug
resistance for HIV protease and reverse transcriptase compared to using sequence data alone.

26

Another group reported mean R2 values of >0.95 for regression with ANN using a subset
of HIV sequences restricted to subtype B with the data filtered to remove rare variants [71]. Their
classification accuracy was less impressive. Structural data can also be represented by molecular
mechanics calculations on protein-drug complexes. Molecular interaction components calculated
between a drug and 36 single mutants of HIV protease were used for SVM classification of
resistance and showed improved accuracy over using sequence alone [70]. These results were
comparable to our earlier results, but for a much smaller number of sequences. Feature vectors
derived from a four-body statistical potential and n-grams were applied in [72]. This approach also
used explicit atomic models for the protease and therefore only a few hundred mutants were
included for classification and regression. Their reported accuracy was worse than ours.
Our approach preserves structural information using Delauney Triangulation derived from
a single protein structure, and is applicable to any mutant, while eliminating the expensive step of
calculating molecular properties for models of every mutant structure.
2.4.3 Redundancy in the data

One of the original motivations for exploring graphbased encoding of protein structures
was to remove unnecessary data while retaining the critical features for machine-learning based
analysis of structure and function [61]. Earlier work [65], which used compressed encoding, hinted
that the redundancy was not completely removed from the data. Our use of PCA on the data
demonstrated that further compression is possible because the majority of the variance in the data
could be captured with 50–60 dimensions instead of the 210 used in the original representation.
This strongly suggests that we may be able to extract patterns of mutations associated with drug
resistance from the structural data itself.
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2.4.4 Inhibitor specific patterns of drug resistance

Another important difference between generative machine learning and more conventional
algorithms is that it is logically consistent to apply generative machine learning across categories.
Since the RBM is essentially measuring how well it can reconstruct a given data point, it makes
sense to ask whether an RBM trained on one inhibitor such as ATV could reconstruct data for a
different inhibitor such as DRV. Examples of two inhibitors, Darunavir and Atazanavir are shown
in Fig. 3 which demonstrates the diversity of drug chemistry used to inhibit HIV PR.
Figure 3 The chemical structures for a sulfonamide-containing (DRV) and nonsulfonamide-containing (ATV) inhibitor are shown here. These demonstrate the variety of
chemistry used in inhibitors

The inhibitors segregate into two main classes in the cross-training analysis. Cross-training results
in high accuracy for most inhibitors, with the exception of DRV and TPV, which both incorporate
sulphonamides. DRV and TPV, predict each other with reasonable accuracy (92.5%), however
they show worse prediction for other inhibitors. While this could be due to chemical similarity, it
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could also be due to these being second generation or salvage inhibitors where the full spectrum
of resistance mutations has not had time to evolve.

2.5 CONCLUSION

Generative machine learning algorithms such as the RBM are well-suited to the prediction
of drug resistance in HIV PR, and likely will work on other systems as well. The graph-based
structure/sequence encoding used in this and related work removes much of the redundancy in the
data, but does not remove it all. This result suggests that even more efficient encoding schemes
are possible. The RBM was used to analyze similarities in resistance profiles for different clinical
inhibitors. The analysis suggests that there are at least two main classes of inhibitors for HIV PR.

29

3 MACHINE LEARNING APPROACH FOR SELECTING DELINEATIVE DRUG
RESISTANCE MUTANTS OF HIV-1 PROTEASE*

*

In the process of submission.

Abstract

Background: Highly active antiretroviral therapy (HAART) is a combination of different
antiretroviral drugs, currently prescribed as an anti-AIDS treatment. Upcoming drug resistance to
HAART have caused an alarming concern in its treatment. Several groups have tried to predict
drug resistance from genotype data by a variety of algorithms. It becomes a challenging task to
identify certain important, representative HIV-1 PR mutants from a pool of several hundred
mutants.
Results: This paper attempts to answer this question by implying some supervised and
unsupervised machine learning techniques. Support vector machine (SVM) and random forest
(RF) are supervised machine learning techniques, while K means, hierarchical agglomerative and
divisive clustering are categorized as unsupervised machine learning techniques, and we have
implemented them to identify important PR mutations from a pool of mutants. By intersecting
sequences with the 2 clustering techniques, 32, 257, 287, 76, 53, 104, 331, and 304 sequences felt
common with hierarchical and divisive clustering for each of the ATV, DRV, FPV, IDV, LPV,
NFV, SQV and TPV inhibitors. Further, intersecting these with the K means clustering selected
only 20, 37, 2 and 35 sequences for FPV, LPV, NFV and SQV inhibitors.
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Conclusion: In this study, we have effectively encoded HIV-1 protease sequence and structure
information in a vector by using Delaunay triangulation. The effectiveness is tested by SVM and
RF learning algorithms. We then have utilized 3 un-supervised machine learning algorithms for
identifying most representative mutants. These resistant sequences with mutants will enable
laboratory studies of the molecular mechanisms of resistance.

3.1 INTRODUCTION

Acquired Immunodeficiency Syndrome (AIDS) is one of the deadliest pandemic disease
with approximately 1.1 million people living with HIV in US [86]. A total of 26 licensed drugs
are used in anti-AIDS therapy targeting viral entry, reverse transcription, integration and
maturation [87]. An important enzyme, HIV protease (PR) causes processing of viral precursor
proteins after budding of virus from the host cell during the maturation stage [88]. Inhibitors to
block this PR and subsequently its proteolytic activity have been effective in controlling infections
[89]. Highly active antiretroviral therapy (HAART) is a combination of different antiretroviral
drugs, currently prescribed as a anti-AIDS treatment [90]. Upcoming drug resistance to HAART
have caused an alarming concern in its treatment [90]. Several groups have tried to predict drug
resistance from genotype data by a variety of algorithms [91] [92] [93]. It becomes a challenging
task to identify certain important, representative HIV-1 PR sequences from a pool of several
hundred sequences. This paper attempts to answer this question by implying some supervised and
unsupervised machine learning techniques. Support vector machine (SVM) and random decision
forest (RF) are supervised machine learning techniques, while K means, hierarchical
agglomerative and divisive clustering are categorized as unsupervised machine learning
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techniques, and we have implemented them to identify important PR sequences from a large pool
of mutants. While some groups have tried to provide valuable insights into characterization of
novel HIV drug resistance mutants using clustering, multidimensional scaling and SVM based
feature ranking from relational clinical databases, ours attempts to select resistant sequences from
existing pool [94]. We have generated a novel pipeline for such analysis as depicted in Figure 4.
Figure 4 Pipeline for analysis: Sequence of steps for the analysis are shown.

3.2 RESULTS

3.2.1 Efficient encapsulation of protein sequence and structure using Delaunay triangulation:

We have efficiently encoded a combined three-dimensional protein structure and sequence
information of HIV-1 protease using a graph generated by Delaunay triangulation [95]. Structure
template 3OXC [96] was used for HIV-1 PR. All the PR mutant sequences can be efficiently
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represented using 210-dimensional vectors with a constant dimensionality. These structure vectors
along with their respective resistance fold values were fed in SVM to check the efficiency of
encapsulation. SVM is widely used as a supervised learning classifier in the classification area
[97]. A clear delineation between resistant and non-resistant sequences through SVM can indicate
encapsulation efficiency. In this experiment a three, five and ten fold validations were performed
for SVM analysis in a linear kernel mode by implementing Python sklearn toolbox [98]. The results
are shown in Table 4.
Table 4Confidence Intervals, P-Value, Sensitivity, Specificity, Positive and Negative Predictions,
Balanced Accuracy and Standard Deviation for all the inhibitors from SVM and Random Forest (RF)
analysis

Parameters
ATV
Accuracy
95 Percent
Confidence Interval
P-Value
Sensitivity
Specificity
Positive Prediction
Value
Negative Prediction
Value
Balanced
Accuracy
Stddev
FPV
Accuracy
95 Percent
Confidence Interval
Parameters
P-Value
Sensitivity
Specificity

Three Fold
(SVM,RF)
0.9742,0.9863
(0.9697,
0.9782),(0.983,
0.9891)
<2e-16,<2e-16
0.9727,0.9878
0.9757,0.9847
0.9765,0.9848

0.9709,0.99
(0.9666,
0.9748),(0.9866,
0.9928)
<2e-16,<2e-16
0.9759,0.9957
0.9661,0.9844
0.9661,0.9845

0.9491,0.9964
(0.9439,
0.954),(0.9896,
0.9993)
<2e-16,<2e-16
0.9472,0.9976
0.9511,0.9954
0.9512,0.9952

0.9719,0.9877

0.9758,0.9957

0.9471,0.9977

0.9742,0.9863

0.971,0.9901

0.9491,0.9965

4.10528,4.099989
0.9602,0.9998
(0.9554,
0.9647),(0.9991, 1)
Three Fold (SVM,RF)
<2e-16,<2e-16
0.9482,1.0000
0.969,0.9997

Five Fold (SVM,RF)

4.10528,4.101648
0.9379,0.9995
(0.9325,
0.9429),(0.9983,
0.9999)
Five Fold (SVM,RF)
<2e-16,<2e-16
0.9278,1.0000
0.9451,0.9990

Ten Fold (SVM,RF)

4.10528,4.103662
0.9386,0.9772
(0.9336,
0.9434),(0.9646,
0.9862)
Ten Fold (SVM,RF)
<2e-16,<2e-16
0.9266,1.0000
0.9474,0.9539
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Positive
Prediction Value
Negative
Prediction Value
Balanced
Accuracy
Stddev
IDV
Accuracy
95 Percent
Confidence Interval
P-Value
Sensitivity
Specificity
Positive
Prediction Value
Negative
Prediction Value
Balanced
Accuracy
Stddev
DRV
Accuracy
95 Percent
Confidence Interval
P-Value
Sensitivity
Specificity
Positive
Prediction Value
Negative
Prediction Value
Balanced
Accuracy
Stddev
NFV
Accuracy
95 Percent
Confidence Interval
P-Value

0.9569,0.9997

0.9233,0.9991

0.9273,0.9568

0.9626,1.0000

0.9483,1.0000

0.9469,1.0000

0.9586,0.9998

0.9364,0.9995

0.937,0.9769

4.104171,4.097711

4.104171,4.104209

4.104171,4.104669

0.9671,0.9821
(0.9627,
0.9712),(0.9783,
0.9853)
<2e-16,<2e-16
0.9617,0.9966
0.9723,0.9674
0.971,0.9685

0.9571,0.9826
(0.9525,
0.9613),(0.9782,
0.9863)
<2e-16,<2e-16
0.9547,0.9963
0.9593,0.9688
0.9566,0.9700

0.9635,0.9965

0.9575,0.9961

0.9433,1.0000

0.967,0.9820

0.957,0.9825

0.9502,0.9869

4.105339,4.102193
0.9895,0.9806
(0.9858, 0.9924),(0.977,
0.9838)

4.105339,4.104663
0.9772,0.9827
(0.9726,
0.9812),(0.9789, 0.986)

0.9505,0.986
(0.946,
0.9548),(0.9757,
0.9928)
<2.2e-16,<2e-16
0.9387,1.0000
0.9617,0.9739
0.9585,0.9708

4.105339,4.102954
0.9745,0.9764
(0.9699,
0.9786),(0.9704,
0.9815)
<2e-16,<2.2e-16
0.9643,0.9954
0.9793,0.9733
0.9559,0.8603

<2.2e-16,<2.2e-16
0.996,0.9913
0.9865,0.9717
0.9709,0.9665

<2e-16,<2.2e-16
0.9683,0.9915
0.9813,0.9771
0.9601,0.9652

0.9982,0.9927

0.9852,0.9945

0.9833,0.9992

0.9912,0.9815

0.9748,0.9843

0.9718,0.9843

4.108086,4.058676
0.9658,0.9921
(0.9613,
0.9698),(0.9895,
0.9942)
<2e-16,<2e-16

4.108086,4.055835
0.953,0.9915
(0.9484,
0.9574),(0.9883,
0.9941)
<2e-16,<2e-16

4.108086,4.057195
0.9496,0.9902
(0.9451,
0.9538),(0.9808,
0.9958)
<2e-16,<2e-16
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Sensitivity
Specificity
Positive
Prediction Value
Negative
Prediction Value
Balanced
Accuracy
Stddev
LPV
Accuracy
95 Percent
Confidence Interval
P-Value
Sensitivity
Specificity
Positive
Prediction Value
Negative
Prediction Value
Balanced
Accuracy
Stddev
Parameters
TPV
Accuracy
95 Percent
Confidence Interval
P-Value
Sensitivity
Specificity
Positive
Prediction Value
Negative
Prediction Value
Balanced
Accuracy
Stddev
SQV
Accuracy

0.9692,0.9993
0.9612,0.9848
0.9704,0.9851

0.9559,0.9995
0.9493,0.9831
0.9609,0.9842

0.9538,1.0000
0.9441,0.9805
0.9571,0.9808

0.9597,0.9993

0.9428,0.9995

0.9399,1.0000

0.9652,0.9920

0.9526,0.9913

0.9489,0.9902

4.107777,4.104829
0.9754,0.9901
(0.9714,
0.9789),(0.9872,
0.9925)
<2e-16,<2e-16
0.9791,0.9993
0.9718,0.9809
0.971,0.9812

4.107777,4.106061
0.965,0.9921
(0.9608, 0.9688),(0.989,
0.9946)
<2e-16,<2e-16
0.9643,0.9995
0.9656,0.9846
0.965,0.9851

4.107777,4.104499
0.9639,0.9915
(0.9599,
0.9676),(0.9826,
0.9966)
<2.2e-16,<2e-16
0.9567,1.0000
0.971,0.9828
0.9704,0.9836

0.9797,0.9993

0.9649,0.9995

0.9575,1.0000

0.9754,0.9901

0.965,0.9921

0.9639,0.9914

4.106898,4.106167
Three Fold (SVM,RF)
0.9701,0.9859
(0.9649,
0.9746),(0.9826,
0.9886)
<2e-16,<2e-16
0.9512,0.9918
0.9774,0.9805
0.9423,0.9785

4.106898,4.107035

4.106898,4.10363

Five Fold (SVM,RF)

Ten Fold (SVM,RF)

0.9523,0.9901
(0.9465,
0.9576),(0.9869,
0.9927)
<2e-16,<2e-16
0.9067,0.9929
0.9697,0.9879
0.9197,0.9849

0.9538,0.9956
(0.9485,
0.9588),(0.9913,
0.9981)
<2e-16,<2e-16
0.9136,1.0000
0.9697,0.9942
0.9224,0.9816

0.981,0.9926

0.9645,0.9943

0.966,1.0000

0.9643,0.9862

0.9382,0.9904

0.9416,0.9971

4.108681,4.089722
0.9681,0.9988

4.108681,4.088172
0.9559,0.9986

4.108681,4.089285
0.9357,1.0000
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95 Percent
Confidence Interval
P-Value
Sensitivity
Specificity
Positive
Prediction Value
Negative
Prediction Value
Balanced
Accuracy
Stddev

(0.9637,
0.9722),(0.9976,
0.9995)
<2e-16,<2e-16
0.9622,1.0000
0.9722,0.9976
0.9595,0.9976

(0.9512,
0.9602),(0.9969,
0.9995)
<2e-16,<2e-16
0.941,1.0000
0.9664,0.9971
0.9517,0.9972

0.9741,1.0000

0.9588,1.0000

0.9398,1.0000

0.9672,0.9988

0.9537,0.9985

0.9321,1.0000

4.112695,4.101274

4.112695,4.107813

(0.9305,
0.9406),(0.9957, 1)
<2.2e-16,<2e-16
0.9123,1.0000
0.9519,1.0000
0.9295,1.0000

4.112695,4.10336

We found a high accuracy, sensitivity, 95 percent confidence, positive and negative prediction
values and specificity for all the tested inhibitors. For all the PIs the accuracy values range from a
low of 0.96 to a high of 0.98, while sensitivity and specificity range from 0.95-0.99 and 0.96-0.98,
respectively. A 95 percent confidence values ranged from 0.95-0.99, while the positive and
negative prediction values ranged from 0.95-0.97 and 0.95-0.99, respectively. These values were
consistent for all the tested fold validations. We further validated these SVM results with another
supervised machine learning algorithm, random decision forest (RF) analysis. These high SVM
and RF parameters conclusively separates the resistant and non-resistant data into two distinct
categories thereby demonstrating an efficient encapsulation
3.2.2 Hierarchical agglomerative clustering for classifying resistance mutations:

Hierarchical agglomerative clustering is a ’bottom up’ approach, where each observation
starts in its own cluster, followed by a continuous merging with upwards hierarchical movement
[99]. The choice of an appropriate metric is important in influencing the shape of the clusters.
Distance plays an important factor in cluster distribution and various distance techniques such as
euclidean, squared euclidean, manhattan, maximum and mahalanobis distances have been implied
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in such clustering [100]. In this analysis, an manhattan or euclidean metric seems appropriate as
we are interested in an ’absolute magnitude’, identifying vectors having similar mean values [101,
102]. Although, the run-time of agglomerative and divisive clustering are exhaustive and slow
with O(n 2 log(n)) and O(2n ) complexities [103], we didn’t had any run-time issues with our data
on an IBM system x3850 X5 server. Hierarchical agglomerative clustering starts with an most
disparate observation which initiates a splinter group, which subsequently reassigns observations
that are closer to the splinter group than to the old party and results in a division of the selected
cluster [102]. Euclidean distances were calculated using function ’dist{stats}’ from cluster
package in R [103]. This function computes and returns the distance matrix computed between the
rows of a data matrix [104]. Hierarchical cluster analysis was performed using function
’hclust{stats}’ from cluster package in R [105]. Agglomeration method of ’complete linkage’ for
finding similar clusters was utilized. With complete linkage, for ’n’ observations there are ’n-1’
merges with ’2n−1 ’ possible orderings for the leaves in a dendrogram [102]. Figure 5 depicts the
sequences clustered with hierarchical clustering, interestingly most of the high resistance fold
sequences with class 2 were clustered in first 10 clusters for all the selected inhibitors, delineating
a clean separation between non-resistant and resistant sequences.
Figure 6 Hierarchical and divisive clustering on sequences: Most of the high resistance
fold sequences with class 2 were clustered in first 10 clusters for all the selected inhibitors
through both hierarchical and divisive clustering delineating a clean separation between nonresistant and resistant sequences.
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Table 5 shows results from hierarchical agglomerative clustering. We found a total of 1433, 657,
4349, 3018, 7616, 2594, 2092 and 1070 sequences in first 10 clusters for each of the ATV, DRV,
FPV, IDV, LPV, NFV, SQV and TPV inhibitors.

Table 5 Number of sequences for each of the 3 classes clustered via Hierarchical (H) clustering
for first 10 clusters
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Cluster
Class ATV
DRV
Number
H
H
Total
1433
657
1

2

3

4

5

6

7

8

9

FPV
IDV H
H
4349 3018

LPV
NFV
SQV
TPV
H
H
H
H
7616 2594 2092 1070

0
1

0
88

72
4

50
559

6
50

0
130

56
16

63
24

69
35

2

10

8

41

6

0

19

4

1

0
1

11
212

1
29

16
103

0
0

45
231

188
502

24
84

35
1

2

41

2

73

8

0

213

8

2

0
1

22
229

0
26

1877
150

16
4

570
253

4
280

239
181

0
0

2

11

19

8

0

0

341

135

16

0

19

2

10

422

24

32

0

97

1

21

15

6

102

44

369

8

87

2
0

3
0

7
0

8
266

0
0

11
30

4
8

10
8

1

13

70

465

16

3

205

487

8

2
0

7
0

3
0

0
16

0
1

22
1

71
52

8
306

1

0

0

70

18

136

29

227

8

2
0

10
2

32
0

7
0

0
0

0
36

5
0

40
125

1
133

1

294

24

7

0

9

34

204

120

2
0

132
2

5
0

3
68

0
2005

0
3

4
0

28
17

7
9

1

17

0

316

141

20

8

4

8

2
0

18
16

128
88

0
227

4
0

12
0

3
2

1

90

91

22

131

157

77

17

4

2

57

5

24

0

49

10

12

6
82

5
8

0
3

0
26

0

39
10

0

0

15

0

19

1

26

9

66

29

2

82

2

33

0

0

54

0

2

2

38

0

10

0

3

16

68

3.2.3 Divisive clustering for classifying resistance mutations:

Divisive clustering is a ’top down’ approach, where all the observations start in one cluster
and splitting occurs recursively as one moves down the hierarchy [102]. Divisive cluster analysis
was performed using function ’diana{cluster}’ from cluster package in R [104]. This algorithm
constructs a hierarchy of clusterings, starting with one large cluster containing all ’n’ observations
with divisions until each cluster contains only a single observation [104]. The logical flag was set
to true, as the input matrix was considered a dissimilarity matrix obtained from vectors euclidean
distances. Table 6 shows results from divisive clustering.
Table 6 Number of sequences for each of the 3 classes clustered via Divisive (D) clustering for
first 10 clusters
Cluster
Class ATV
DRV FPV
IDV
LPV
NFV
SQV
TPV
Number
D
D
D
D
D
D
D
D
Total
2125
771 4152 2798 5774 4059 3273 1210
1

2

3

4

0
1

0
367

6
1

0
162

0
46

0
294

4
26

0
31

29
55

2

136

4

37

8

249

8

1

13

0
1

10
104

0
0

18
87

35
685

7
356

236
502

41
295

26
1

2

41

4

30

303

643

222

154

2

0
1

33
264

0
17

64
864

0
4

648
301

29
637

243
258

0
0

2

33

2

7

32

8

356

78

16

0

6

0

1967

16

0

4

0

1

40

5

6

7

8

9

10

1

61

0

291

150

4

94

454

10

2

13

16

10

19

53

33

90

4

0
1

25
138

136
363

10
291

0
145

0
80

32
172

0
0

38
34

2

23

1

8

4

7

10

2

11

0
1

0
13

0
0

101
345

452
277

36
40

48
606

20
81

134
337

2

8

3

9

11

124

76

42

5

0
1

38
76

32
34

0
1

0
277

20
64

8
66

46
209

32
6

2

108

3

7

34

76

31

34

1

0
1

4
145

45
13

4
16

0
1

5
90

0
306

5
26

126
82

2

270

17

7

2

27

231

8

37

0
1

5
44

2
32

0
15

0
46

2245
255

0
86

36
81

45
42

2

89

17

17

10

7

36

50

1

0
1

0
18

8
10

0
18

0
419

4
85

0
117

481
463

52
34

2

53

5

8

27

46

83

44
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We found a total of 2125, 771, 4152, 2798, 5774, 4059, 3273 and 1210 sequences in first 10
clusters for each of the ATV, DRV, FPV, IDV, LPV, NFV, SQV and TPV inhibitors.
3.2.4 K means clustering for classifying resistance mutations:

K means method aims to partition the points into K groups, such that the sum of squares
from points to the assigned cluster centre’s is minimized, it at-most tries to put all cluster centre’s
at the mean of their Voronoi sets [105]. For a set of observations {x1, x2, ..., xn}, K means
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clustering aims to partition the ’n’ observations into K sets, S = {S1, S2, ..., Sk}, so as to minimize
the within-cluster sum of squares (WCSS), where µi is the mean of points in set Si [103].
K means analysis was performed using function ’kmeans{stats}’ from cluster package in
R [104]. The centers or the number of clusters, K were chosen with the silhouette method with K
maximum of 100. Figure 5 shows the optimal cluster cutoffs for each of the inhibitors. We also
tried other techniques for validating optimal cluster determination by silhouette, some of them
were elbow method, clusGap, Mclust, and cascadeKM.
Figure 5 Silhouette method for cluster cutoffs: Optimal cluster cutoffs for each of the
inhibitors. A: ATV, B: DRV, C: FPV, D: IDV, E: LPV, F: NFV, G: SQV, and H: TPV

3.2.5 Sequences/mutations selected from intersection between hierarchical agglomerative,
divisive and K means clustering:
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Table 7 and Figure 6 shows the sequences selected from intersection between hierarchical
agglomerative, divisive and K means clustering.
Table 7Number of sequences common via hierarchical (H), divisive (D) and K means (K)
clustering. Cluster numbers shown in brackets

Category
H and D
H, D and
K

ATV
32
0

DRV
257
0

FPV
287
20 (66)

IDV
76
0

LPV
53
35 (61) ,
2 (31)

NFV
104
2 (12)

SQV
331
5 (58), 6
(63), 3
(73), 21
(85)

TPV
304
0

Figure 7 A Venn diagram showing number of mutations found common via hierarchical,
divisive and K means clustering: Number of mutations found common ivia hierarchical, divisive
and K means clustering. Optimal cluster numbers are shown in brackets

Different cluster combinations between hierarchical agglomerative and divisive were performed
as shown in Figure 4. Each cluster of hierarchical was intersected with each cluster of divisive, the
cluster combination giving maximum common sequences was selected to intersect with K means
clusters. With intersections between hierarchical agglomerative and divisive clustering, for ATV
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D and ATV H, cluster combination 1659 gave maximum number of common sequences (94),
belonging to class 1 with resistance fold of 55. DRV D and DRV H, cluster combination 1711
gave maximum number of common sequences (38), belonging to classes 0, 1 with resistance folds
of 0.4 and 51. FPV D and FPV H, cluster combination 198 gave max number of common sequences
(149), belonging to classes and resistance folds of 1, 23; 1, 53; 1, 70; 2, 400; and 0, 0.3. IDV D
and IDV H, cluster combination 1113 gave max number of common sequences (146), belonging
to classes and resistance folds of 1, 15; 2, 186.9 and 2, 500. LPV D and LPV H, cluster combination
538 gave max number of common sequences (104), belonging to classes and resistance folds of 0,
2.3; 1, 3.2; 1, 21; 1, 76; 1, 82; 2, 100.7; 2, 126; and 2, 280.0. NFV D and NFV H, cluster
combination 932 gave max number of common sequences (62), belonging to classes and resistance
folds of 1, 48; 1, 68; 1, 72; 1, 78; 1, 97.2; and 2, 286. SQV D and SQV H, cluster combination
1327 gave max number of common sequences (132), belonging to classes and resistance folds of
0, 1; 0, 1.8; 1, 14.0; 1, 14.0; 1, 33; 1, 56; 1, 93; 2, 181; 2, 242; 2, 249.8; 2, 350.0; 2, 591.5; and 2,
1000. TPV D and TPV H, cluster combination 793 gave max number of common sequences (76),
belonging to classes and resistance folds of 2, 200; and 0, 0.4. These sequences were then
intersected with clusters from K means clustering, and 20 (cluster 66), 37 (Cluster 61, 31), 2
(Cluster 12), and 35 (Cluster 58, 63, 73 and 85) sequences felt in common clusters for each of the
FPV, LPV, NFV and SQV inhibitors.
3.3 Materials and methods

3.3.1 Datasets used for the study:
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The genotype-phenotype datasets were downloaded from the Stanford HIV drug resistance
database [106] (http://hivdb.stanford.edu/pages/genopheno.dataset.html). For HIV-1 PR, the
inhibitors atazanavir (ATV), nelfinavir (NFV), ritonavir (RTV), indinavir (IDV), lopinavir (LPV),
tipranvir (TPV), saquinavir (SQV), and darunavir (DRV) were tested. All the datasets were preprocessed using the methods and the cutoff values described previously in [93]. The results of the
expansion for each of the HIV-1 PR inhibitors were: for SQV 10258 sequences of 1722 isolates,
DRV 5973 sequences of 607, LPV 10239 sequences of 1444, NFV 10911 sequences of 1771, IDV
10537 sequences of 1730, ATV 8430 sequences of 1141, FPV 10521 sequences of 1681 and TPV
7363 sequences of 847.
3.3.2 Pre-processing/Expansion of the datasets:

Insertion, deletion, or presence of stop codon in sequences has been removed for data
unification. A sequence with 99 amino acids representing protease HIV-1 PR has been used for
this data. Datasets usually have multiple mutations at the same sites; these datasets were expanded
to multiple sequences with single amino acids at each location to represent a single amino acid
sequence for each mutant protein. For example, if one 99-amino acid mutant sequence has two
different types of amino-acids, and another site has three, this one sequence needs to be represented
in six different sequences each having only one amino-acid substitution. The time complexity to
minimize such calculations have been explained in detail [93] and been applied for pre-processing
this dataset. Each of these sequences were accompanied by their inhibitor resistance fold values.
The relative resistant fold values for sequences in each of the inhibitors ranged from 0-800-fold
resistance. Furthermore, the expanded datasets with sequences have been allotted a unique
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identifier number which will help to trace back the sequences and its resistance fold change after
analysis.
3.3.3 Encoding structure and sequence with Delaunay triangulation:

A graph-based encoding system was utilized to represent the sequence and structural
information of the protein [95]. The structurally adjacent pairs of amino acids were represented in
form of a vector of the 210 unique pairs of 20 standard amino acids. A amino acid type for each
adjacent pair in structure was the parameter utilized for calculating all the 210 vectors. Such graphbased encoding of sequence and structure have been proven to be an promising technique for faster
and accurate predictions of resistance from sequence in HIV infections [106]. The X-ray crystal
structure for HIV-1 PR (3OXC) was used as a template for creating Delaunay triangulation [96].
3.3.4 Cutoffs for resistance/susceptibility for each drug:

For SVM and RF analysis, for all the HIV-1 PR inhibitors those mutants with the relative
resistant fold > 3.0 were classified as resistant, denoted as 1. For K means, hierarchical and divisive
clustering, relative resistant 99 denoted as class 1 and anything above relative resistant fold of 100
were classified as class 3.
3.3.5 SVM and RF analysis:

To understand the efficiency of Delaunay triangulation encoding, randomly chosen (k-1)/k
sequences (some are drug resistant, while others are non-drug resistant) were selected for training
the classifier and the remaining 1/k sequences were used for testing. The SVM and RF parameters

46

for each of the inhibitors are shown in Table 4. A three, five and ten fold validation was performed
for both RF and SVM analysis.
3.3.6 Clustering analysis with K means, Hierarchical and Divisive clustering:

Optimal number of clusters for K means clustering were selected through silhouette
method [106]. 10, 87, 98, 92, 87, 94, 95, and 97 clusters were found to be optimal for sequences
with ATV, DRV, FPV, IDV, LPV, NFV, SQV and TPV inhibitors. Figure 4 shows the optimal
cluster cutoffs for each of these inhibitors. For divisive clustering the height of 60 was found to be
optimal for all the inhibitors. For hierarchical clustering, the height of 60 was also found to be
optimal for ATV, DRV, IDV, LPV, SQV and TPV inhibitors, while 65 and 70 heights were found
to be optimal for FPV and NFV inhibitors. Hierarchical and divisive clustering was performed
with resistance levels on 210 vectors for each of the sequences. Table 5 and Table 6 shows number
of sequences for each of the 3 classes clustered in first 10 clusters.
3.4 DISCUSSION

Drug resistance in HIV-infected individuals is a serious problem and there are numerous
mutations that can occur in any of the 99 amino acids of HIV-1 protease sequence. Thus, making
it extremely difficult to select representative mutants for detailed research in the laboratory. In this
study, we have effectively encoded HIV-1 protease sequence and structure information in a vector
by using Delaunay triangulation. The effectiveness is tested by two supervised machine learning
algorithms. We then have utilized 3 un-supervised machine learning algorithms for identifying
most representative mutants. By intersecting sequences with the 2 clustering techniques, 32, 257,
287, 76, 53, 104, 331, and 304 sequences felt common with hierarchical and divisive clustering
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for each of the ATV, DRV, FPV, IDV, LPV, NFV, SQV and TPV inhibitors. Further, intersecting
these with the K means clustering selected only 20, 37, 2 and 35 sequences for FPV, LPV, NFV
and SQV inhibitors. This approach selected sequences with L10F, I13V, L33F, E35D, M36I,
N37D, I54V, I84V and L90M, L10I, M46I, L63P and A71V mutations. Some important
characteristics of these resistant mutations from selected sequences are summarized below. With
L10F mutation, a hydrogen bond that is crucial for effective inhibition is lost with NFV [109].
L10I mutation impairs replication complex and confers resistance to SQV [110]. L33F increases
non-covalent interactions in the hydrophobic pocket, it also increases rigidity of the 30s and 80s
loops compared to wild type protease with expansion of the S1/S1 prime sub site which alters
DRV binding [111]. E35D mutation is seen to increase flexibility of the flaps affecting the
conformational equilibrium between the closed and semi open conformations of the free protease
[112]. Double mutant (V82A and L90M) both confer strong resistance to ritonavir (RTV), and the
molecular dynamic simulations reveals a contraction of the ligand binding pocket which is
enhanced by I54V mutation [113]. A71V and M36I are also important secondary mutations
associated with resistance [114]. These sequences will enable laboratory studies of the molecular
mechanisms of resistance.
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4 STUDIES OF FOUR INVESTIGATIONAL PROTEASE INHIBITORS WITH
HIV-1 PROTEASE BEARING DRUG RESISTANT SUBSTITUTIONS V32I, I47V AND
V82I*

*In the process of submission
Abstract

Antiviral inhibitors of HIV-1 protease are effective in HIV/AIDS therapy, although drug resistance
is a severe problem. This study examines the effects of four investigational inhibitors against HIV1 protease with drug resistant mutations of V32I, I47V and V82I (PRTri) that models the inhibitorbinding site of HIV-2 protease. Inhibitors GRL-0249, GRL-0519, GRL-0739 and GRL-1111
introduce diverse chemical modifications on the darunavir scaffold, and form new interactions
with wild type protease. The measured inhibition constants for PRTri mutant range from 17-40
nM or three-orders of magnitude worse than for wild type enzyme. The X-ray crystal structure of
PRTri mutant in complex with GRL-1111 determined at 1.5 Å resolution shows minor changes in
interactions with inhibitor compared with the corresponding wild type PR complex. Instead,
mutation to Ile82 induces two alternate conformations for the side chain of Arg8 with new
interactions with inhibitor and Leu10.

4.1 Introduction

HIV/AIDS is a pandemic disease with about 37 million people infected worldwide [115].
HIV infection can be controlled by antiviral drugs targeting different stages of viral replication,
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however, the genetic diversity of the virus and rapid selection of drug resistant strains pose a severe
challenge [116,117]. The retrovirus HIV includes two types, HIV-1 and HIV-2, and HIV-1 is
subdivided into three groups (M, O, and N) and subtypes with different geographical distribution.
HIV-2 infections are common in West Africa, however, some drugs designed for HIV-1 are not
effective for HIV-2 infections [118].

One important class of antiviral drugs targets the viral protease (PR), which is crucial for
production of infectious virus. PR processes cleavage sites in Gag-Pol region during viral
maturation to produce individual structural proteins [119]. This aspartic protease is catalytically
active as a dimer of 99-residue monomers [120]. Clinical inhibitors bind in the active site cavity
of the enzyme and block binding of substrates. Some HIV-1 PR inhibitors, including amprenavir
(APV), are significantly less potent against HIV-2 infections probably because the amino acid
sequences of HIV-1 and HIV-2 PRs show only about 40% sequence identity [121]. In addition to
its natural genetic diversity, the virus has evolved resistance mutations for all clinical protease
inhibitors (PIs) [122]. Single, major mutations decrease binding of inhibitor, however, they can be
deleterious for viral replication. Resistance mutations can alter the catalytic activity, binding
affinity and stability of PR [9,10]. The virus evolves additional mutations that compensate by
restoring effective viral replication in the presence of inhibitor [123].

HIV-1 PR with drug resistant mutations V32I, I47V and V82I (PRTri) has been evaluated
as a model for inhibition of HIV-2 PR. The three mutations in PRTri alter residues in the inhibitorbinding cavity (Figure 8) and represent the changes in the inhibitor binding site of HIV-2 protease.
APV showed poor inhibition of both PRTri and HIV-2 PR at 15- and 19-fold worse than for HIV-
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1 PR, while darunavir (DRV) and saquinavir (SQV) were effective inhibitors of all three enzymes
[124]. Moreover, the individual mutations of V32I, I47V and V82I are associated with resistance
to one or more clinical inhibitors [122]. Hence, PRTri was chosen to evaluate the efficacy of
investigational inhibitors for drug-resistant mutants and HIV-2 PR.

Figure 8: Sites of mutation in HIV-1 PR dimer with inhibitor GRL-1111. PR is shown as
green ribbons with sites of the three mutations, V32I, I47V and V82I, indicated as grey spheres,
GRL-1111 is shown in red bonds.

The four investigational antiviral inhibitors were designed on the DRV scaffold (Figure 9)
with the aim of introducing new interactions of the P2 group with PR. They exhibited potent
antiviral activity on wild type and drug resistant strains of HIV-1.
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Figure 9: Structures of the clinical and investigational inhibitors used in this study.

Inhibitor GRL-0519 contains tris-tetrahydrofuranylurethane (tris-THF) as the P2 ligand
instead of bis-THF in DRV [127-129]. The third THF group introduces new water-mediated
hydrogen bond interactions with Gly27 and Arg87 in the PR dimer interface. GRL-1111 has a
novel P2 bis-THF group with a basic amine that forms direct and water-mediated hydrogen bond
interactions with the main chain carbonyl oxygen and amide of Gly48 in the PR flap [130]. GRL0739 has a novel tricycle cyclohexyl-bis-tetrahydrofuranylurethane at P2, and resembles GRL0519 in its new water-mediated interactions [131]. This inhibitor showed favorable penetration of
the central nervous system (CNS) in an in vitro model [18].

GRL-0249 has a 3-(S)-N-

methoxycarbonyl amino substituted cyclopentyltetrahydrofuranyl (Cp-THF) at the P2 group [132].
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The carbamate NH forms hydrogen bonds interactions with the main chain of Gly48 similar to
those of GRL-1111 and the carbamate carbonyl has a water-mediated interaction with the
guanidinium group of Arg8’. Crystal structures confirmed the presence of new interactions of wild
type PR with the P2 groups of these inhibitors compared to DRV. Therefore, we hypothesized they
would show good inhibition of PRTri. Inhibition constants were measured for the four inhibitors,
and a high resolution X-ray structure was determined for PRTri in complex with GRL-1111.

4.2 Materials and methods

4.2.1 Inhibitors
Amprenavir (APV) (HPLC purity of 99.7%) was obtained from the AIDS Reagent
Program, Division of AIDS, NIAID, NIH. Compounds GRL-0519, GRL-1111, GRL-0739 and
GRL-0249 (>95.0% purity by HPLC) were provided by Dr. Arun Ghosh at Purdue University.

4.2.2 Protein purification

The clone for triple mutant PRTri (V32I, I47V and V82I) includes optimizing mutations of
Q7K, L33I, and L63I to decrease autoproteolysis, and C67A, C95A to eliminate cysteine-thiol
oxidation [134]. Protein was expressed in E. coli BL21 and purified from inclusion bodies as
described previously [135,136] using gel filtration followed by reverse phase chromatography and
refolding. Samples were concentrated to 5.0 mg/mL for crystallization or diluted for kinetic assays.

4.2.3. Protein crystallography
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PRTri was mixed with inhibitor (dissolved in dimethylsulfoxide) at a molar ratio of 1:5.
Crystals were grown at room temperature by hanging drop vapor diffusion. Each drop contained
1 μL protein and 1 μL reservoir solution. Crystals of PRTri-GRL-1111 were grown from 0.1 M
sodium acetate, pH 4.6, and 2 M NaCl. Crystals were cryo-protected in 30% glycerol and flash
frozen in liquid nitrogen. X-ray diffraction data were collected on the SER-CAT 22ID beamline,
Advanced Photon Source, Argonne National Laboratory (Argonne, IL), and processed using
HKL-2000 [137]. The structure was solved by molecular replacement with PR complex with APV
(3NU3) [138] using CCP4i Phaser [139,140]. The structure was refined with SHELX-2014 [141],
followed by REFMAC5 [141]. COOT [143] was used for visualization and refitting. Alternate
conformations were modeled according to the electron density maps. Anisotropic B factors were
applied in the refinement. Structural figures were made using PyMOL [144]. Atomic coordinates
and structure factors for PRTri with GRL-1111 have been deposited in the PDB [145] with ID:
XXXX.

4.2.4. Enzyme kinetic assays
Kinetic parameters of PRTri were determined in 3-5 replicate runs by monitoring hydrolysis
of fluorescence substrate derived from the HIV-1 p2/NC cleavage site: Abz-Thr-Ile-Nle-p-nitroPhe-Gln-Arg-NH2 (BACHEM H-2992) (where Abz is anthranilic acid, Nle is norleucine, and pnitro-Phe is p-nitrophenylalanine). Samples were equilibrated at 37 C for 5 minutes prior to
initiating the reactions. Enzyme activity was measured at 37 C using a PolarStar Optima
microplate reader (BMG Labtech) with excitation wavelength at 340 nm and emission wavelength
at 420 nm, as described previously [138,146]. To determine catalytic efficiency, 10 µL of PRTri
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(final well concentration of 40-100 nM determined by active site titration with APV) was mixed
with 100 µL reaction buffer (100 mM MES pH 5.6, 400 mM NaCl, 1 mM EDTA, and 5%
glycerol). Reaction was initiated by adding 100 µL substrate (12-96 µM final concentration).
Initial velocities (V0) were determined using MARS software (BMG Labtech). The Km and kcat
were determined by fitting data to the Michaelis-Menten plot of V0 vs [substrate].
For inhibition studies, 10 µL PRTri was mixed with 98 µL reaction buffer and 2 µL inhibitor
in DMSO (final well concentration 0-40 µM). Reaction was initiated with 90 µL substrate (final
well concentration 60 µM). IC50 values were determined using SigmaPlot (Systat Software) by
non-linear regression curve fitting to a dose-response plot of V0 vs [inhibitor]. Ki values were
calculated using the equation for tight-binding inhibitor of Ki = (IC50 - 0.5[E]) / (1 + [S]/Km) [147].
For the urea denaturation assay, 10 µL PRTri was mixed with 100 µL reaction buffer
containing 8 different urea concentrations (0-4 M). Reaction was initiated with 90 µL substrate
(final well concentration 60-72 µM) in 0-4 M urea. The urea concentration in each well remained
the same throughout the experiment. A plot of V0 vs [urea] was constructed using SigmaPlot
(Systat Software) and sigmoidal curve fitting used to determine the urea concentration for 50%
maximum velocity (UC50).

4.3 Results

4.3.1 Kinetic Parameters, Inhibition and Stability of PRTri mutant

Kinetic parameters were determined for PRTri hydrolysis of a fluorescent substrate analog
at 37 C prior to assaying the effects of inhibitors under the same conditions. PRTri mutant had kcat
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of 299 ± 48 μM/min and Km of 72 ± 17.7 µM. The catalytic efficiency (kcat/Km) of 4.2 μM-1 min1 is similar to that value of 6.5 μM-1 min-1 for wild type enzyme at 26 C [147].

Ki values were measured for investigational inhibitors (Table 8). Clinical inhibitor APV
gave a Ki value of 2.5 nM for PRTri mutant, which is identical to the value reported previously
using a different peptide substrate in an HPLC assay [126]. APV showed 16-fold worse inhibition
of the mutant compared to wild type PR, as reported earlier using a different assay [126]. These
investigational inhibitors, however, had Ki values ranging from 16.7 to 39.5 nM for the mutant.
GRL-0249 with Ki of 16.7 nM was the best of the four inhibitors, and GRL-0519 and GRL-0739
were the worst with Ki values of 38.4 and 39.5 nM, respectively. The tested inhibitors were
significantly less effective for the mutant compared to Ki values of 2-10 pM reported for the wild
type enzyme [128,130,132,133].

The stability of the mutant and wild type enzymes were assessed by measuring enzyme
activity under urea denaturation. A UC50 value of 0.97 +/- 0.05 M was obtained for PRTri mutant.
In comparison, the wild type enzyme gave a UC50 value of 0.70 +/- 0.07 M under the same
conditions. These values suggest the mutant dimer is somewhat more stable than the wild type
protease.

4.3.2 Crystallographic analysis of PRTri complex with GRL-1111

The crystal structure of PRTri with GRL-1111 was solved at 1.50 Å resolution in the P21212
space group, and refined to R/Rfree values of 13.4/17.2 %. Crystallographic statistics are listed in
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Table 9. The asymmetric unit of the crystal structure contained a dimer of PRTri, and the inhibitor,
GRL-1111, was bound at the active site in two alternate orientations with an occupancy ratio of
0.5/0.5. The solvent was modeled with 133 water, 1 glycerol and 4 formic acid molecules from the
crystallization and cryo-protectant solutions. The crystal structure of PRTri/GRL-1111 was
compared with the corresponding complex of wild type PR (PDB ID: 5BRY), which was
determined at 1.34 Å resolution in the same space group with isomorphous unit cell dimensions
and contained PR dimer with inhibitor bound in two orientations with 0.6/0.4 relative occupancy
[130]. The two dimer structures superimposed with a low RMSD value of 0.23 Å on Cα atoms.
The interactions of PRTri with inhibitor were analyzed in comparison to those in wild type
PR complex. GRL-1111 forms six direct hydrogen bonds with PRTri, excluding the interactions of
the central hydroxyl with the catalytic Asp25 and 25’ (Figure 10).
Figure 10: Hydrogen bond interactions of PRTri with inhibitor GRL-1111. Protein is shown
as grey bonds, inhibitor in green bonds. Dotted lines indicate hydrogen bond interactions with
interatomic distances in Å.
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Additionally, it forms water-mediated interactions with flap residues Gly48, Ile50 and
Ile50’, while one orientation of inhibitor (designated as the “major” conformation) has a watermediated interaction with the carboxylate side chain of Asp29. PR-inhibitor hydrogen bond
interactions are conserved in the mutant and wild type complexes with differences of no greater
than 0.2 Å in length for the major inhibitor conformations. GRL-1111 was designed to incorporate
an amine on bis-THF at P2 that forms a new direct hydrogen bond interaction with the carbonyl
oxygen of Gly48, a water-mediated interaction with the amide of Gly48 in the flap region, and a
second water-mediated interactions with the side chain of Asp29. These interactions of GRL-1111
cannot occur with clinical inhibitor DRV, which lacks the basic amine. However, the minor
inhibitor conformation of GRL-1111 in PRTri complex has lost the second water and its interaction
with Asp29.
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The hydrophobic side chains of residues 32, 47 and 82 are important components of the
PR binding site for substrates or inhibitors. In wild type PR/GRL-1111, Val82 interacts with the
P1 and P1’ groups of inhibitors, while Val32 and Ile47 contribute to the binding site for P2 and
P2’ groups (Figure 11).
Figure 11: The hydrophobic side chains of residues 32, 47 and 82.

Ile82 in the mutant has similar interactions with inhibitor P1 and P1’ as seen for Val82 of
wild type enzyme. The P2 group of GRL-1111 has similar interactions with Val32 and Ile32, while
Val47 in the mutant has shifted to form new interactions with P2 compared to Ile47 in the flap.
The P2’ group has gained van der Waals interactions with Ile32’ and lost contacts with Val47’
relative to those in the wild type structure.
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In addition to the contacts with inhibitors, these residues interact with adjacent PR side
chains. The side chains of residue 32 and 47 form hydrophobic contacts with each other and with
neighboring side chains, as shown in Figure 12.

Figure 12: Figure depicting side chains of residue 32 and 47 forming hydrophobic contacts
with each other and with neighboring side chains.

Val32 and Val32’ have similar hydrophobic contacts with Thr80/80’ and Ile84/84’, while
Val32’ forms an additional van der Waals interaction with the side chain of Ile50 at the tip of the
flap. Flap residues Ile47 and 47’ show conserved hydrophobic contacts with Lys45/45’, Ile54/54’
and Ile50’/50, while Ile47’ has an additional contact with Val56’ in the flap and Leu76’ but loses
a contact with Asp30’. The majority of these internal hydrophobic contacts are retained in the PRTri
mutant, despite the altered side chains of V32I and I47V. Compared to the wild type complex,
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both Ile32 and 32’ lose one hydrophobic contact to Val47 and Val47’, respectively. However,
Ile32 has gained a contact with Ile50’ in the mutant relative to the wild type complex. Val47 in the
mutant has shifted by about 0.5Å and rotated by 180°, thus forming three extra hydrophobic
contacts to the P2 group of the inhibitor but losing contacts with Asp30, Ile54, Ile50’, and Lys45.
While Val47’ has the same orientation as the wild type residue, it loses two contacts to the P2’
group of the inhibitor and has fewer contacts with Lys45’ and Leu76’ in the mutant.
The Ca atoms of both Val47 and 47’ shift by about 0.5Å relative to their location in wild
type PR. The most significant change illustrated for Val47 in mutant relative to Ile47 in wild type
PR. This shift enables Val47 to form 3 new hydrophobic contacts with the P2 group of inhibitor,
while losing contacts with neighboring side chains of Asp30, Lys45, Ile54 and Ile50’.
Mutation of Val82 to the longer Ile introduces new van der Waals interactions and
significant changes in the side chain conformation of Arg8. In the wild type PR complex, the side
chain of Arg8 has a single conformation that forms a key intersubunit ion pair with Asp29’ and no
contacts with inhibitor. In the PRTri/GRL-1111 structure, the longer side chain of Ile82/82’ appears
to induce two alternate conformations of Arg8/8’ with equivalent changes in both subunits. The
guanidinium group of one conformation of Arg8 retains the ion pair with Asp29’ and also forms a
new van der Waals contact with the P2 group of inhibitor. The second conformation of Arg8 is
rotated away to form van der Waals contacts with Leu10 instead of the intersubunit ionic
interaction with Asp29’. The second conformation of Arg8/8’ is not observed in the corresponding
complex of PRTri/DRV, possibly because DRV lacks the extra amine of GRL-1111. These changes
may be due to the local environment, since a multiple mutant PR20 has similar alternative
conformations of Arg8/8’ related to the substitution of the larger Phe side chain instead of Leu10
(Figure 13) [149].
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Figure 13: Interactions of alternative conformations of Arg8’ with neighboring side chains
and inhibitor. Mutant is in magenta bonds with alternate conformation of Arg8’ in cyan and GRL1111 in green. Wild type PR and inhibitor are grey. Dotted lines indicate ionic interaction, and
dashed lines indicate hydrophobic interactions. CH-pi interactions with the aromatic P1 group of
inhibitor are indicated by a single dashed line.

4.4 Discussion

The four tested investigational antiviral compounds were poor inhibitors (Ki values of 16.7
to 39.5 nM) of HIV-1 PRTri despite their excellent pM inhibition of wild type enzyme
[128,130,132,133]. Analysis of protease-inhibitor interactions in the crystal structure of
PRTri/GRL-1111 revealed the loss of one water mediated polar interaction in one orientation of
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inhibitor and small changes in hydrophobic contacts. In particular, Val47 loses hydrophobic
contacts with flap residues Lys45, Ile50’ and Ile54 compared to those of wild type complex. The
most substantial change compared to the wild type complex occurred for mutated residue
Ile82/82’, where the larger side chain produces two alternate conformations for the side chain of
Arg8/8’. One conformation of the guanidinium group of Arg8/8’ forms new van der Waals
contacts with Leu10 and the P2 group of GRL-1111 instead of its typical intersubunit ion pair with
Asp29’/29. We previously reported the crystal structures of PRTri complexes with APV, DRV and
SQV [126]. These structures exhibited a single conformation for Arg8/8’, except for the APV
complex which had two alternate conformations for Arg8’ side chain in one subunit and new van
der Waals contacts with Ile82’ and Leu10’ similar to those in the PRTri/GRL-1111 structure.
Moreover, only a single conformation was observed for Arg8/8’ in our structures of HIV-2 PR
with different inhibitors [126,150]. This change in conformation seen for Arg8/8’ in PRTri/GRL1111, comprising partial loss of its intersubunit ion pair and new intra-subunit interactions, might
be expected to alter the stability of the mutant, however, the UC50 for urea denaturation remains
close to the value for wild type PR. In contrast, PR mutant with the single substitution of R8Q,
which completely eliminated the ion pair with Asp29’, showed decreased stability with UC50 of
0.7 relative to wild type enzyme [151]. Overall, the loss of internal contacts among flap residues
and disruption of the Arg8 – Asp29’ ion pair are consistent with molecular dynamics simulations
suggesting substitutions V32I, I47V and V82I in HIV-2 PR decrease the hydrophobic interactions
with APV and DRV [152].

This new structure of PRTri/GRL-1111 shows how drug resistant mutations of V32I and
I47V on opposite sides of the S2/S2’ subsites can partially compensate for altered hydrophobic
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interactions with inhibitors and other protease residues, while mutation V82I induces alternate
conformations of Arg8/8’ and introduces new interactions with Leu10 and the P2 group of GRL1111. These changes appear to be specific for this combination of inhibitor and mutant.

Table 8: Ki values (nM) of tested inhibitors.

PRTri

APV

GRL-1111

GRL-0249

GRL-0519

GRL-0739

2.5 ±

31.4 ± 3.9

16.7 ± 0.8

38.4 ± 1.2

39.5 ± 6.1

0.16

0.002 [130]

0.002 [132]

0.006 [150]

0.010 [149]

0.9
PR
[147]

Values for wild type enzyme are from listed citations.

Table 9: Crystallographic Data Collection and Refinement Statistics.
(Values in parentheses are given for the highest resolution shell.)

Space group
Unit cell dimensions: (Å)
A
B
C
Resolution range (Final Shell )(Å)
Unique reflections
Rmerge (%) overall (final shell)
I/σ(I) overall (final shell)
Completeness (%) overall (final shell)
Redundancy (final shell)
R (%)
Rfree (%)

PRTri/GRL-1111
P21212
58.57
86.52
45.32
50-1.50 (1.55-1.50)
37,188 (2,865)
5.9 (49.2)
26.6 (3.1)
96.8 (76.4)
6.7 (4.1)
13.4
17.2
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No. of solvent atoms
RMS deviation from ideality
Bonds (Å)
Angle distance (degree)
Average B-factors (Å2)
Wilson B-factor
Main-chain atoms
Side-chain atoms
Whole chain atoms
Inhibitor
Solvent

151
0.020
2.29
17.7
17.0
23.6
20.2
15.7
28.3
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5 SPERMINE AND OXACILLIN STRESS RESPONSE ON THE CELL WALL
SYNTHESIS AND THE GLOBAL GENE EXPRESISON ANALYSIS IN METHICILLIN
RESISTANCE STAPHYLOCOCCUS AUREUS

Pawar S, Yao X, Lu C. 2018. Spermine and oxacillin stress response on the cell wall
synthesis and the global gene expression analysis in Methicillin-resistance Staphylococcus aureus.
Genes & Genomics. 41:43–59. https://doi.org/10.1007/s13258-018-0735-8.

Abstract:

Methicillin-resistant Staphylococcus aureus (MRSA) is a rapidly emerging bacteria
causing infection, which has developed resistance to most of the beta-lactam antibiotics because
of newly acquired low-affinity penicillin-binding protein (PBP2a), which can continue to build the
cell wall when beta-lactams block other PBPs. Exogenous spermine exerts a dose-dependent
inhibition effect on the growth of Escherichia coli, Salmonella enterica serovar, and S. aureus.
Selection of an MRSA Mu50 derivative which harbors mutation on PBP2 gene (named as MuM)
showing spermine resistance and which confers a complete abolishment of spermine-beta-lactam
synergy was identified. To further investigate the gene expression changes, a transcriptome
profiling of MuM against Mu50 (wild-type) without any treatment, MuM and Mu50 in response
to high dose spermine and Mu50 in response to spermine-beta-lactam synergy at 15, 30 and 60 min
time points was performed. Functional annotation was further performed to delineate the metabolic
pathways associated with the significant genes. A significant down-regulation in the iron
regulatory system, potassium channel uptake and polyamine transport system with an up-
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regulation in general stress response sigB dependent operon in MuM strain at 15, 30 and 60 min
time points with spermine treatment compared to Mu50 strain was observed. Analysis of sperminedependent synergy with beta-lactams on cell wall synthesis revealed that it significantly reduces
the degree of cross-linkage on cell wall with no change in trypsin digestion pattern of purified
PBPs and without affecting PBPs expression or PBPs acylation by Bocillin. A strong relation
between PBP2 protein and general stress sigB response, iron, potassium and polyamine transport
systems was observed. SigB regulon should be activated on stress, which was not seen in some of
our previous studies where it was down-regulated in wild-type Mu50 strain with spermine stress.
Here, an intriguing finding is made where there seems to be a correction of this abnormal response
of no SigB induction to a significant induction by PBP2 mutation. In MuM strain, a significant
downregulation of KdpABC operon genes at 15, 30 and 60 min time points on spermine stress is
seen, which seems to be absent without spermine treatment. Since KCL has been found to protect
the cell against spermine stress in wild-type strain by induction of KdpABC operon, it fails to do
so in MuM strain underlying the importance of PBP2 protein in spermine stress. Analysis of
spermine-dependent synergy with beta-lactams on cell wall synthesis revealed that it significantly
reduces the degree of cross-linkage on cell wall with no change in trypsin digestion patterns of
purified PBPs and without affecting PBPs expression or PBPs acylation by Bocillin. Furthermore,
spermine does not help in enhancing the binding of beta-lactams to PBPs and binding of spermine
to PBPs does not cause conformational changes to PBPs, as tested with trypsin digestion patterns.
Future studies on the molecular mechanism of spermine interactions with these systems hold great
potential for the development of new therapeutics for MRSA infections.
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5.1 INTRODUCTION

Methicillin-resistant Staphylococcus aureus (MRSA) is an opportunistic pathogen that
causes hospital and community-acquired infections varying from mild skin lesions to severe, lifethreatening conditions like pneumonia, sepsis, and endocarditis [154, 155]. The resistance occurs
because of newly acquired low-affinity penicillin-binding protein (PBP2a), which can build the
cell wall when other PBPs are blocked by beta-lactams [156]. In Staphylococcus aureus, there are
four native PBPs (PBP1-4), and one acquired PBP2a is attributive to MRSA [157]. Beta-lactam
antibiotics irreversibly occupy the serine residue at the active site of penicillin-binding proteins
(PBPs) forming a stable ester-linked acyl-enzyme which inhibits the transpeptidation process
necessary for cell wall cross-linking [158-173]. Thus, MRSA seems to regulate a complex gene
expression profiling when challenged with beta-lactams. Many studies have shown that exogenous
spermine may become toxic to Staphylococcus aureus [174-177]. Exogenous spermine exerts a
dose-dependent inhibition effect on the growth of E. coli, Salmonella enterica serovar, and
Staphylococcus aureus. Recently, we reported that exogenous spermine might affect cell wall
synthesis through its interactions with PBP2 and PBP2-associated multienzyme machinery to
enhance the killing effects of beta-lactam antibiotics. The two possible ways of making MRSA
sensitive by spermine-beta-lactam synergy can be by reducing the cross-linkage of peptidoglycan
layer or by inhibiting cell growth. The PBP2 itself or enzymatic activities associated with the
PBP2-dependent complex in cell wall synthesis could be a potential target of spermine, so we
sought to identify a spontaneous mutation derived MRSA strain (MuM) conferring spermine
resistance and studying how this mutation can contribute to resistance. The identified MuM strain
showed a 32-fold increase in tolerance of growth inhibition by spermine and has completely lost
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the spermine-beta-lactam synergy. Genome re-sequencing revealed a deprivation of transpeptidase
activity with a 7-bp deletion within the pbpB gene, which may result in perturbation of cell wall
synthesis and change the peptidoglycan structure. We also found that the degradation of MuM cell
wall materials was significantly faster than that for the Mu50 control which suggested that cell
walls of MuM may be less cross-linked and more susceptible to hydrolysis due to the defects in
PBP2 protein [177, 178]. Thus, MuM is seemed to adjust its metabolic activities to compensate the
defective cell wall synthesis. A detailed transcriptomic analysis of how MuM and Mu50 responds
to spermine and spermine-beta-lactam synergy is still unknown. Therefore, in the current study,
we have systematically compared Mu50 (wild-type), and MuM strain response to spermine alone
(high dose) or in combination with b-lactam (oxacillin) (both at low dosages) using microarrays.
To study the exogenous spermine effects on cell wall synthesis through its interactions with PBP2
and PBP2-associated multienzyme machinery to enhance the killing effects of beta-lactam
antibiotics, comparisons between Mu50 and MuM strains are performed using cell wall synthesis
and transcriptomic assays. For transcriptomic experimental design, a three time-point (0, 30, and
60 minutes) microarray data with replicates was generated for each of the two strains treated with
spermine, oxacillin or both, and comparisons were made to study within and between treatment
(MuM) changes when compared to the control strain (Mu50). Complementation of pbpB protein
was also performed to validate the changes in treatment strain. While some groups have reported
genome-wide transcriptional profiling of Staphylococcus aureus against the cell wall active
antibiotics [177], ours is one of the first attempts in understanding this species response to spermine
and beta-lactams with mutated PBP2 protein.
5.2 METHODS
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5.2.1 Bacterial strains, plasmids, growth conditions and isolation of spermine-resistant
mutants:

Staphylococcus aureus Mu50 (ATCC 700699), RN4220 (kindly provided by R. P. Novick,
Newyork, USA) and Escherichia coli DH5 alpha (Bethesda Research Laboratories, Maryland,
USA) were used for this study. Spontaneous mutants of MRSA Mu50 (oxacillin MIC of 512 μg/ml
and spermine MIC of 1 mM at pH 8.0) were isolated by spreading 1×108 CFU of log-phase cells
onto spermine-containing plates (2 to 8 mM, pH 8.0) maintained in the Luria-Bertani (LB) medium
and incubated overnight at 37°C. One independent colony was found resistant to spermine (up to
32 mM) in broth and on plates designated as MuM. For cell wall composition analysis,
Staphylococcus aureus Mu50 (ATCC700699), E. coli DH5 alpha (Bethesda Research
Laboratories, Maryland, USA) and Top10 (Invitrogen, Massachusetts, USA) strains were
employed. The plasmids and primers used in this study are listed in Table 10.
Table 8 Plasmids used in this study

Plasmids

Relevant
characteristics
pBAD/HisA Expression vector,
Amp
pBAD/HisD Expression vector for
producing N
terminal His tag
fusion, Amp
pBAD/HisE Expression vector for
producing C
terminal His fusion,
Amp
pH6NpBAD/HisD expressing
PBP1
N-HisPBP1

Source or
reference
Invitrogen
This study

This study

This study
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pH6CPBP2
pH6NPBP3
pH6NPBP4
pBP2a

pBAD/HisE expressing
C-HisPBP2
pBAD/HisD expressing
N-HisPBP3
pBAD/HisD expressing
N-HisPBP4
pBAD/HisA expressing
no tag PBP2a

This study
This study
This study
This study

Both E. coli and Staphylococcus aureus strains were grown and maintained in the LB medium
cultured in 20mM Tris-HCl at the indicated pH when needed. For E. coli, ampicillin was added to
the medium as necessary at 100 μg/ml. Antibiotics were added to the medium as necessary at the
following concentrations for maintenance of plasmids: ampicillin, 100μg/ml for E. coli;
kanamycin, 25μg/ml for E. coli, 50μg/ml for S. aureus; erythromycin, 10μg/ml for S. aureus;
chloramphenicol, 10μg/ml for S. aureus.
5.2.2 Complementation of pbpB:

The pbpB gene was reported to be transcribed independently or as a polycistronic RNA
from its upstream prfA promotor [185]. To ensure optimal expression, a 3.2 kb fragment covering
both prfA and pbpB were amplified by PCR from Mu50 genomic DNA with the primers 5’-CGC
GGA TCC ACA CAT ACT TGT ACT TGC CTC-3’ (forward) and 5’-CGC GGC GCC GAG TGG
ATT AGT TGA ATA TAC CTGTTA ATC CAC CGC TG-3’ (reverse). The resulting PCR product
was cloned into the BamHI and NarI sites of the shuttle vector pCN38. The recombinant plasmid
pYX9 was first cloned into and extracted from E. Coli and then electroporated into Staphylococcus
aureus RN4220 [167, 194]. Plasmid DNA isolated from recombinant strains of RN4220 was
subsequently introduced into Mu50 and MuM strains by electroporation. Meanwhile, empty vector
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(pCN38) did not rescue the phenotypes in MuM (data not shown).
5.2.3 Transcriptional profiling conditions:

Staphylococcus aureus Mu50 and MuM were grown in Tris-buffered LB (pH 7.5), and
cultures in the exponential phase (optical density at 600 nm [OD600] of around 1.0) were
immediately treated with the RNA protection reagent (Qiagen, Maryland, USA) before harvesting.
In the first condition, Mu50 and MuM strains were treated with 1mM spermine, and RNA isolated
at 0, 15, 30 and 60-minute time-points with spermine and single 0 min time-point without
spermine. In the second condition, three treatments of Mu50 strain with 1mM spermine, 2ng/μl
oxacillin and a combination of 1mM spermine, 2ng/μl oxacillin were grown for one hour
subsequently followed by RNA isolation. Spermine at 0.5mM was able to potentiate oxacillin MIC
in MRSA strain Mu50, from 512μg/mL to less than 1μg/ml. Spermine MIC alone is 2-4mM.
Therefore, spermine at 0.5 or 1 mM, oxacillin at 1μg/ml, 2μg/ml or 16μg/ml, are the concentrations
that do not affect bacterial growth when used alone, but they can kill MRSA when used in
combination [167]. So we chose to use 1/4 MIC instead of 1mM for spermine, and 1/32 MIC
instead of 16μg/mL for oxacillin. RNA samples were extracted from cells with phenol (Fisher,
Massachusetts, USA), digested with RNase-free DNase I (Roche, Indiana, USA) to remove
genomic DNA, and purified with RNeasy mini columns (Qiagen, Maryland, USA). The cDNA
synthesis, fragmentation, and terminal labeling were carried out as per the protocols of the
manufacturer (Affymetrix, Massachusetts, USA). Labeled cDNA was hybridized to the GeneChip
Staphylococcal aureus genome array. After scanning, the images were processed with GCOS 1.4
software (Affymetrix, Massachusetts, USA). The data was generated for two independent
biological replicates.
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5.2.4 Microarray analysis:

Mas 5.0 normalization was performed for all the files at 0-minute time point for Mu50 and
MuM strains and strains with MuM-PBP2 and Mu50-PBP2 complementation plasmid [195]. For
calculating upregulated genes, in control of all the P (present) call intensity values were considered
for analysis and all the M (marginal) and A (absent) calls were regarded as 100. For treatment, all
the genes with intensity values above 500 were considered in the analysis. This rigorous approach
gave us significant differences amongst various comparisons avoiding any false positive and false
negative results. The exact opposite criteria were applied to find down-regulated genes. Fold
changes (greater than 1.5 and less than 1.5) with MuM-Mu50 and (MuM with PBP2)-(Mu50 with
PBP2) were taken to find up and down-regulated genes in MuM strain. A similar method was used
for comparison of MuM and Mu50 at 15, 30 and 60-minute time points with spermine treatment.
Up and down-regulated genes were calculated and compared with 0-minute time point with no
spermine treatment. All the microarray data were analyzed using library ’Affy’ package [196] on
R platform [197]. Heat maps were generated using library ’gplots’ [198]. Heat maps were
developed on Z scores, which were calculated by heatmap.2 function of gplots [Z score = (raw
intensity - average)/standard deviation]. MA plots [199] for showing differentially expressed genes
were calculated as follows: M = Logarithm to base 2 (Treatment/Control), A= 1/2×Logarithm to
base2 (Treatment×Control). MA plots were made on R platform with ‘plotMA’ limma
Bioconductor package [200].
5.2.5 Cell wall composition analysis:
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MRSA strain Mu50 was grown in LB broth (pH 8.0, w/ 20mM Tris cl) at 37°C with
aeration. Cultures were supplemented with 0.5 mM spermine (Spm) and/or 1 ng/μl oxacillin (Ox)
at OD600 of 0.5 and cell growth was continued for 4 hours before harvesting. Isolation of cell wall
peptidoglycans and the analysis of the muropeptides by reverse-phase HPLC were carried out by
CeCo Labs from Tubingen University, Tubingen, Germany (www.cecolabs.de).
5.2.6 Protein cloning, expression, and purification:

Phusion polymerase (NEB) was used to amplify pbp1 (or pbpA), pbp3 (or pbpC), pbp4 (or
pbpD) genes with no N-terminal signal peptide and the putative transmembrane (TM) domain (at
N-terminus of PBP1 and PBP3 and C-terminus of PBP4) from gDNA of MRSA Mu50 strain.
Three plasmids were generated (pH6N- PBP1, pH6N-PBP3, and pH6N-PBP4) from PCR product
cloned into pBAD/HisD expression vector digested at PstI/EcoRI restriction enzyme sites. The
constructs encoded hexahistidine tag at the N-terminus of PBP1, PBP3, and PBP4 plasmids.
Recombinant proteins covering residues M37-D744 for PBP1, Q44-K691 for PBP3, and T25H400 for PBP4 were expressed from these plasmids. A similar approach was utilized for
expressing periplasmic polyamine-binding protein PotD and PotR of the potABCD operon. The
PCR products were digested with HindIII and EcoRI and cloned into vector pBAD/HisD (5’ blunt
end of PCR product ligating to SmaI site on the vector) at SmaI/HindIII and SmaI/EcoRI sites. We
labeled these plasmids as pH6NnSP-PotD and pH6N-PotR (hexa-histidine tags were fused to Nterminus of PotD and PotR). Top10 E. coli strains harboring plasmid of interest were grown at
30°C in LB medium containing 100 μg/ml ampicillin. At 0.6 to 0.8 OD600 cultures were
supplemented with 0.2 percent arabinose and grown for additional 4 hours. After harvestation cells
were suspended in buffer A containing 20 mM sodium phosphate [NaPi] buffer, pH 7.4, and
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500mM NaCl. The buffer was also supplemented with EDTA-free protease inhibitors (Roche),
which after centrifugation at 20, 000×g for 30min at 4°C a HisTrap HP column (GE) preequilibrated with Buffer A was applied on soluble fraction. Bound proteins were eluted by
increasing concentrations of imidazole (final conc. 500 mM) in a gradient-dependent manner.
Protein concentration was performed on fractions using Aminco Ultra-4 centrifugal filter unit
(Millipore, Massachusetts, USA) with buffer to 20 mM Tris-HCl (pH 7.6). The region encoding
amino acids W59 to S716 for pbp2 (or pbpB) gene was PCR amplified (Phusion, NEB, New
England, USA) from Mu50 genomic DNA with specific primers. Digestion was done with
BspHI/SmaI restriction enzymes and the product was cloned in vector pBAD-HisE at NcoI/SmaI
sites (pH6C-PBP2 having C-terminal hexahistidine tag) which were subsequently introduced into
E. coli Top10 for expression its protein. Induction with 0.2 percent arabinose for 4 hours at 30°C
was performed at a log-phase culture. This was followed by French press at 17,000 psi in Buffer
A. After centrifugation (20, 000g × for 30 min) pellet was suspended in Buffer A (0mM CHAPS,
10 percent glycerol, 0.1 percent Sarkosyl (detergent) at pH to 9.0. Stepwise elution was performed
with detergent-containing Buffer A with 500mM imidazole using a HisTrap HP column (GE).
Concentration was performed using Aminco Ultra-4 centrifugal filter unit (Millipore,
Massachusetts, USA) at buffer 20 mM Tris-Cl (pH7.6). mecA gene (without first 69 bases for its
N-terminal anchoring region of 23 amino acids) was amplified from Mu50 gDNA and cloned into
NcoI/HindIII restriction enzyme sites of pBAD/HisA for expressing PBP2a protein. The resulting
plasmid pPBP2a was transformed into E. coli Top10 which was induced at a log-phase culture
with 0.2 percent arabinose for 4 hours at 30°C. Cells were disrupted by French press at 17,000 psi
in buffer Q (20mM Tris-Cl, pH7.6). The supernatant after centrifugation at 20, 000g × for 30 min
was subjected to ammonium sulfate fractionation. At 30 percent saturation fraction was
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precipitated and concentrated by Aminco Ultra-4 centrifugal filter unit (Millipore, Massachusetts,
USA). The obtained protein sample was further diluted with Q buffer and applied to HiTrap Q HP
column (GE, California, USA). Gradient elution with buffer Q containing 1M KCl was also used,
and samples were concentrated again with Aminco Ultra-4 centrifugal filter unit to change the
buffer to 20 mM Tris-HCl (pH 7.6).
5.2.7 Construction of expression vector pBAD-HisE:

Expression vector pBAD-HisE was constructed with primer pair’s hisF-5’-GGGCAT
CATCATCATCATCATTGAATTCTGC-3’

and

hisR-5’-GCAGAATTCAATGAT

GATGATGATGATGCCC-3’. Digestion was performed with SmaI/EcoRI to incorporate this
region in the vector pQF50. Further digestion was performed with NcoI/EcoRI enzymes to release
the partial MCS carrying the His6 region.
5.2.8 Bocillin labeling of PBPs:

Purified PBPs (0.04 μg in 20 μl of 20mM Tris-Cl pH8.0) were incubated with Bocillin of
indicated concentrations for 30 min at 37°C with gentle shaking. Staphylococcus. aureus (10 ml)
was harvested at log-phase and the cell pellet was suspended in 200 μl the lysis buffer (50mM Tris
pH7.5, 50mM NaCl, 5-10 μl of lysostaphin (10mg/ml), 5ul of DNaseI (10 Units/μl), 5 μl of RNase
A (200 μg/ml) for 15-20 minutes at 37°C. The lysates obtained were labelled by adding Bocillin
at a final concentration of 5uM and incubated at 37°C for 30 min. Ranges of Bocillin concentration
varied from 0.25-16 uM for concentration-dependent experiments. Samples were pre-incubated
with spermine for 30 min at 37°C prior to Bocillin labeling when needed. Samples were then mixed
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with Laemmli sample buffer and boiled for 5 minutes prior to SDS-PAGE. The gel was rinsed and
scanned with Typhoon scanner with excitation wavelength at 488 nm and emission wavelength at
530 nm. Band intensity was quantified by Image Quant software.
5.2.9 DARTS (Drug Affinity Responsive Target Stability):

The purified protein in buffer containing 1 μg in 20 μl of 50mM Tris-Cl, pH 8.0, 50mM
NaCl, 10 mM CaCl2 was incubated at 37°C with or without 1 mM spermine for 25 min followed
by trypsin digestion (0.075 μg) at 25°C. The reaction was terminated with Laemmli sample buffer
followed by boiling samples for 10min and subsequent SDS-PAGE.
5.3 RESULTS

5.3.1 Transcriptome analysis of MuM strain in response to high dose spermine:
5.3.1.1 Diﬀerences in Mu50 and MuM gene expression at 0-minute time point without spermine
and

reversion

by

MuM/PCN38

complementation:

A total of 220 significantly up and down-regulated genes were found to be expressed in
MuM strain with no spermine treatment at 0-minute time-point. These genes were then compared
with MuM-PBP2 complementation plasmid to see if the changes reverted to wild-type expression
profile. Reversion of expression by MuM-PBP2 was set to genes whose expression levels felt
below -1-fold or went above +1-fold [170]. Three groups were made with genes which reverted to
down-regulation, genes which returned to up-regulation, and genes with no change after
complementation. Doing so 59 genes which completely reverted to up or down-regulation profiles
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and rest 161 genes had no eﬀect by complementation. A heat map in Figure 14 compares these
220 significant genes in MuM and MuM complemented with the PBP2 plasmid.
Figure 14 Heatmap comparing 220 significant genes in MuM and MuM complemented
with PBP2 plasmid strains.

The complete reversion of the up and down regulation status of genes in MuM strain with a PBP2
complemented plasmid is because of mutant PBP2 protein. These genes are selected to validate
the changes occurring with and without spermine treatment in subsequent analysis.
5.3.1.2 Significant down-regulation in the iron transport system and up-regulation of sigB
regulon genes was seen at 15, 30 and 60-minute time points in MuM strain when
compared to Mu50 strain with spermine treatment:

A total of 420, 335, and 332 genes were found significantly expressed in MuM strain at 15,
30 and 60-minute time points when compared with Mu50 strain. These genes were then fed in
DAVID database [170] to perform functional annotation. Genes with the iron transport system
were found to be significantly downregulated with spermine treatment at 15, 30 and 60-minute
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time points in MuM strain compared to Mu50 strain. The list of these genes and their fold change
expression levels are given in Table 11 and Figure 28.
Table 9List of iron regulation, polyamine and potassium transport genes with their significant
fold change expression levels (logarithm to base 2)

Gene
symbol
fhud

Affymetrix
MUM.NOSPM.0 MUM.SPM.15
ID
sa
1.39
0
c914s711 at
fhug
sa
0
− 1.28
c7993s6980
at
fhua
sa
0
0
c5423s4693
a at
fhub
sa
0
− 1.2
c7989s6976
at
htsB
sa
0
− 1.13
c4643s3963
a at
htsC
sa
0
0
c4639s3961
a at
sirA
sa
0
1.18
c1230s1008
at
sirB
sa
0
0
c1172s953
a at
NARG
sa
− 2.99
0
c5574s4827
a at
NIRD
sa
− 1.94
0
c5580s4836
a at
SACOL1640 sa
0
− 1.95
c2711s2285
a at

MUM.SPM.30 MUM.SPM.60
− 2.32

− 2.33

− 1.56

− 1.26

− 1.2

− 1.07

− 1.57

− 1.3

− 1.15

0

− 1.31

0

0

− 1.26

− 1.1

− 1.12

0

0

0

0

0

0
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SACOL1810 sa
c3357s2894
a at
MUTY
sa
c3689s3168
a at
SDAAB
sa
c6092s5283
a at
GLTD
sa
c7412s6438
a at
SACOL0939 sa
c8086s7067
a at
SACOL0770 sa
c8202s7182
a at
SACOL0706 sa
c7993s6980
at
SACOL0705 sa
c7989s6976
at
SACOL0797 sa
c8283s7260
a at
SACOL0796 sa
c8276s7256
a at
SACOL0798 sa
c5353s4626
a at
kdpa
sa
c4298s3650
a at
kdpb
sa
c4292s3644
a at
kdpc
sa
c236s9562
at

0

− 1.57

− 1.61

− 1.69

0

0

− 1.98

− 1.8

0

0

− 1.99

−2

0

0

0

− 2.08

0

1.6

1.56

0

0

− 1.84

0

0

0

0

− 1.56

0

0

0

− 1.57

0

0

0

0

− 1.65

0

0

0

− 2.09

0

0

− 2.07

− 1.58

1.88

− 1.26

− 2.82

− 2.8

0

− 1.74

− 2.52

− 2.38

− 1.54

− 1.49

1.32

0
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pota

potb

potc

potD

sa
c5349s4625
a at
sa
c9028s7925
a at
sa
c795s596 a
at
sa
c803s604 a
at

− 1.01

− 4.01

− 3.66

− 2.58

− 1.97

− 4.68

− 3.94

− 2.7

− 1.36

− 4.31

− 3.83

− 2.48

− 1.69

− 3.71

− 3.01

− 2.06

Figure 15 Bar graph with fold changes (logarithm to base 2) for iron regulation,
potassium and polyamine transport genes in MuM strain at 15, 30 and 60 min time points with
spermine treatment.

A pattern of sigB regulon genes with significant up regulation with spermine treatment was seen
in MuM strain when compared to Mu50 strain. A heat map comparing expression levels of sigB
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operon genes at 0-minute time point with no spermine, 15, 30 and 60-minute time points with
spermine treatment is shown in Figure 15.
Figure 16 Heat map on the fold changes comparing 92 sigB genes in MuM and Mu50
strains at 0 min time-point without spermine treatment, MuM at 0 min time-point without
spermine treatment and with PBP2 complementation, MuM with spermine treatment at 15, 30
and 60 min time points.

Iron is an essential element of redox systems in many gram-positive and negative bacteria’s. Iron
transport systems are needed by bacteria to solubilize external Fe3+. The ABC transporters form
a major iron transport system in gram-positive bacteria. Staphylococcus aureus grows on
transferrin as a sole iron source [173]. There has been a recent demonstration of the production of
siderophores by Staphylococcal strains. Staphylococcus hyicus has been shown to produce at least
two siderophores, staphyloferrins A and B. Siderophores mobilize transferrin iron and donate it to
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siderophore specific ABC transporters in the cytoplasmic membrane [175]. Staphyloferrin A and
B also host catecholamine hormones that support the growth of Staphylococcus aureus.
Staphyloferrin iron is taken up via the HtsABC and SirABC systems, whereas catecholate iron is
taken up by the newly identified SstABCD transport system. Approximately, 42 known transport
proteins of Fe3+ siderophore transport systems have been identified [175]. Expression of iron
repressible outer membrane proteins (IROMPs) binding to specific iron-containing compounds
transport free iron or the iron bound ligand into the cell. The binding of these receptor proteins is
mediated by the iron binding repressor protein and ferric uptake regulator (fur) requiring ferrous
iron as a cofactor [176]. In Escherichia coli fhu operon is composed of the fhuA, B, C and D genes
which are essential for the utilization of ferric siderophores of the hydroxamate-type and mutations
in either one of the fhu genes negatively influence the expression of other fhu genes in the operon.
Transport across the outer membrane is regulated by fhuA, while the cytoplasmic membrane
transport is regulated via fhuC, B, and D genes [177]. By comparing MuM with Mu50 strains at
15, 30 and 60-minute time points with spermine treatment, a significant down-regulation in
HtsABC, SirABC and fhu operons in MuM strain was observed. These significant genes included
iron ion binding proteins, iron-sulfur cluster binding proteins, and iron ABC transporters. There
have been reports for chelation of iron inside the bacterial cell from spermine by forming ternary
complexes with Fe2 and phosphate groups [178] [179]. We have shown that spermine can induce
stress through iron starvation in Staphylococcus aureus which can be the result of altered
intracellular iron status [176]. These signals can be reciprocated by intracellular iron regulators
channels like HtsABC, SirABC, and fhu operons. Significant induction of all these iron acquisition
operons is seen in Staphylococcus aureus on spermine stress indicating a correlation between iron
and spermine. We see a significant down-regulation in iron acquisition operons with mutant PBP2
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protein pitching the importance of PBP2 to iron acquisition and spermine stress. SigB factors have
been shown in various bacteria to be important for survival under extreme conditions influencing
virulence and pathogenicity [180]. SigB regulon is one of the first regulons to response in stress
for bacteria [181]. SigB influences the expression of a variety of virulence genes like alphahemolysin, lipases, and proteases [181-184]. DNA microarray bases study in Staphylococcus
aureus has shown that the sigB regulon influences the expression of at least 251 genes (198 and
53) genes as positively and negatively controlled respectively) [180]. A sixth sigma factor is
necessary to initiate transcription from promoters by binding to the core of RNA polymerase
consisting of five subunits [182] [183]. Most bacteria have additional sigma factors called
alternative sigma factors which can target specific recognition sequences and control specialized
regulons that are activated under stress [179]. Regulators RsbV and RsbW are conserved in all
gram-positive bacteria that have sigB regulon [166]. The kinase activity of RsbW determines
phosphorylation state of the anti-sigma factor antagonist RsbV is subsequently controlling sigma
B activation [182] [184]. The sigma B regulated genes are involved in many cellular processes
including cell envelope turnover, biosynthesis, intermediary metabolism, virulence and membrane
transport processes where the SigB regulon is highly interconnected with other regulatory
networks. Moreover, global regulators of stress response like SarA are also partly under SigB
control [183]. About 92 sigB regulated genes were identified to respond at 0, 15, 30 and 60-minute
time points. At 0-minute time point with no spermine treatment, 49 genes were found to be
significantly up-regulated in MuM strain. When compared with 15, 30 and 60-minute time points
with spermine treatment, 45, 35 and 30 genes of 49 significantly expressed at 0-time point showed
a fold change of greater than 1.5. A pattern of sigB regulon genes with significant up-regulation
with spermine treatment was seen in MuM strain when compared to Mu50. MuM strain deprives
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transpeptidase activity of the PBP2 protein, being abnormal physiology, the bacterium may try to
compensate it by activating sigB regulon in MuM strain without spermine stress. Spermine stress
may exacerbate this condition and can cause a continued up-regulation of this regulon throughout
15, 30 and 60-minute time points on spermine stress. SigB regulon should be activated on stress,
which was not seen in some of our previous studies where it was down-regulated in wild-type
Mu50 strain with spermine stress [166]. Here, we have made an intriguing finding where there
seems to be a correction of this abnormal response of no SigB induction to a significant induction
by PBP2 mutation. It seems to be unclear why SigB regulon was not induced by spermine stress
in

wild-type

strain

which

starts

responding

in

MuM

strain.

5.3.1.3 A total of 488, 146 and 249 significant genes stating diﬀerences between and within
treatments for Mu50 and MuM strains were selected amongst three categories for functional
annotation:

To identify within and between treatment changes, three categories of comparisons were made: 1.
Comparison of Mu50 15, 30 and 60-minute time-points with spermine treatment and Mu50 0
minute time-point without spermine treatment, 2. Comparison of MuM 15, 30 and 60-minute timepoints with spermine treatment was compared with MuM 0 minute time-point without spermine
treatment and 3. Comparison of MuM 15, 30 and 60-minute time-points with spermine treatment
was compared with Mu50 0 minute time-point without spermine treatment. A total of 488
significant genes with a fold change of greater and lesser than 1.5 in category 1, 146 significant
genes in category 2 and 249 significant genes in category three were selected. MA (log ratio to
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mean average) plots for each of these comparisons are plotted in Figure 17 to show the distribution
of these diﬀerentially expressed genes.
Figure 17 MA plots showing differentially expressed genes in Mu50 and MuM
treatments. a.1, a.2, a.3 Mu50 at 15, 30 and 60 min time-points with spermine treatment over
Mu50 0 min time-point without spermine treatment. b.1, b.2, b.3 MuM at 15, 30 and 60 min
time-points with spermine treatment over MuM 0 min time-point without spermine treatment.
c.1, c.2, c.3 MuM at 15, 30 and 60 min time-points with spermine treatment over Mu50 0 min
time-point without spermine treatment.

These

significant

genes

were

further

used

for

functional

annotation.

5.3.1.4 Addition of spermine to Staphylococcus aureus Mu50 strain caused decrease expression
of genes in major central metabolic pathways of carbohydrate biosynthesis, glycolysis and TCA
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cycle, cell structure, fatty acid and lipid biosynthesis and electron transfer chain:

The metabolic pathways and genes involved in Staphylococcus were downloaded from Biocyc
pathway/genome database collection. Functional annotation was performed to delineate the
metabolic pathways associated with the significant genes. Addition of spermine to Staphylococcus
aureus Mu50 strain caused decrease expression of genes in major central metabolic pathways of
carbohydrate biosynthesis, glycolysis and TCA cycle, cell structure, fatty acid and lipid
biosynthesis and electron transfer chain. Percent number of genes involved in each of the processes
aﬀected in MuM and Mu50 strains is shown in Figure 30 with their descriptions in Table 12.
Table 10 List of metabolic processes affected in each of the MuM and Mu50 strains on spermine
stress [+: affected, −: not affected]

Process
number

Metabolic processes

MU50

1.2
2.1
2.2
2.5
2.6
2.7

Interconversions
Amines and polyamines biosynthesis
Amino acids biosynthesis
Carbohydrates biosynthesis
Cell structures biosynthesis
Cofactors, prosthetic groups, electron
carriers biosynthesis
Fatty acid and lipid biosynthesis
Nucleosides and nucleotides
biosynthesis
Other biosynthesis
Alcohols degradation
Aldehyde degradation
Amines and polyamines degradation
Amino acids degradation
C1 compounds utilization and
assimilation

2.8
2.1
2.11
3.1
3.2
3.3
3.4
3.5

MuM

+
+
+
+
+
+

MU50
(percent
genes)
22
100
7
36
1
2

−
+
+
−
−
+

MUM
(percent
genes)
0
57
2
0
0
0.5

+
+

2
1.5

−
+

0
0.5

−
+
+
+
+
+

0
23
66
15
20
43

+
+
+
+
+
+

0.5
3
0
5
2
4
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3.6
3.7
3.8
3.9
3.1
3.11
3.14
3.15
4.2
4.3
5.3
5.4
5.5
5.7
5.8
6.1
7.1

Carbohydrates degradation
Carboxylates degradation
Degradation/utilization/assimilation—
other
Fatty acid and lipids degradation
Inorganic nutrients metabolism
Nucleosides and nucleotides
degradation
Secondary metabolites degradation
Steroids degradation
Methylglyoxal detoxification
Reactive oxygen species degradation
Electron transfer
Fermentation
Glycolysis
Respiration
TCA cycle
Metabolic clusters
Superpathways

+
+
+

21
5
100

+
−
−

3
0
0

+
+
+

8
2
5

−
−
+

0
0
3

+
−
−
+
+
+
+
+
+
+
+

5
0
0
12
11
11
22
19
22
5
9

+
−
+
+
−
+
−
+
−
−
+

5
0
1
12
0
0.5
0
4
0
0
2

Figure 18 Functional annotation was performed to delineate the metabolic pathways
associated with the significant genes using Biocyc pathway/genome database collection.

This transcriptome analyses demonstrated a specific pattern of response in MRSA Mu50 upon high
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dose spermine exposure, suggesting spermine alone may alter the intracellular iron status and
suppress the SigB regulon to exert its toxicity. Combination of two drugs may inhibit bacterial
growth in more complicated ways than the single drug does. As for our case, the synergy of
spermine and beta-lactams may function by spermine facilitating beta-lactams on perturbation of
cell wall synthesis or beta-lactam enhancing spermine attack on unknown targets, or the formation
of a new structural configuration that makes the common target more vulnerable to be attacked by
spermine or beta-lactams. To obtain a better insight of how two agent’s, spermine and beta-lactam
might aﬀect each other to enhance the antibacterial eﬀectiveness, we monitored the global changes
in gene expression patterns over spermine only or oxacillin only and spermine/oxacillin
combination conditions. Considering our isolated Mu50 derivative MuM became spermineresistant and lost spermine/beta-lactam synergy by a specific mutation on PBP2. We therefore
further tested the hypothesis that spermine may interfere with PBP(s) or the coordinated complex
in cell wall synthesis. Three possible ways were selected, by looking at cell wall composition, by
understanding the expression of PBPs on transcriptional level and translational levels upon
challenge by spermine or beta-lactam alone or in combination and looking at the possible
interactions between spermine and PBPs with the recombinant PBPs from Mu50 analyzed via
various biochemical approaches. Down-regulation of various carbohydrate metabolism and
transport genes was observed. Specifically, the expression of genes like phosphoglycerate mutase,
glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase, phosphoglyceromutase,
glucose-6-phosphate isomerase, phosphoglycerate mutase, fructose-bisphosphatase, fructose-1,
6-bisphosphate aldolase and hexulose-6-phosphate synthase were reduced in Mu50 strain with
spermine treatment at 15, 30 and 60-minute time points respectively. These genes and processes
were unaffected in MuM strain with spermine treatment. Polycationic molecules like polyamines
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play important role in maintaining conformation of negatively charged nucleic acids. Bacteria’s
have evolved transport systems that can allow uptake of extracellular polyamines. Polyamine
spermidine can bind to PotD protein causing conformational change triggering a subsequent
conformational change in PotBC leading to ATP hydrolysis and spermidine uptake [186].
Mutations in any of the genes in the potABCD operon abolish polyamine transport [186]. After
comparing MuM strain with spermine treatment at 15, 30 and 60-minute time points, a general
trend in down-regulation of potABCD operon was observed in all the time-points. The similar
pattern was seen in MuM without spermine treatment at 0-minute time point but with low fold
expression which was amplified by an at least one-fold decrease on spermine treatment. Our data
show that there may exist some interaction between potABCD proteins of spermine transport
system and PBP2 protein causing down-regulation of potABCD operon on spermine stress in PBP2
mutant strain compared to wild-type Mu50 strain. Co-immunoprecipitation or Bio-molecular
fluorescence (BiFC) techniques would be needed to confirm these interactions. Potassium uptake
and regulation in bacteria is carried out with kdp operon [188]. KdpABC genes constitute Kdp
operon whose expression is regulated by the KdpDE two-component system in response to
potassium limitation or turgor pressure [189]. The spermine can enter the cell and occlude the
transmembrane pore domain of inwardly rectifying potassium channel (Kir) [200]. When
supplemented with high concentration potassium, we have seen an increase in spermine resistance
by counteracting spermine obstruction on the uptake channel in wild-type Mu50 strain [166].
Addition of potassium (300 mM KCl) has been seen to increase Spermine MIC up to 32-fold [166].
In MuM strain, we see a significant down-regulation of KdpABC operon genes at 15, 30 and 60minute time points on spermine stress which seems to be absent without spermine treatment. Since
KCL has been found to protect the cell against spermine stress in wild-type strain by induction of
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KdpABC operon, it fails to do so in MuM strain underlying the importance of PBP2 protein in
spermine

stress.

5.3.1.5 No significant stimulation of cell-wall-stress stimulon and peptidoglycan synthesis genes
in Mu50 strain with only spermine, or only oxacillin or with combination treatment:

Mu50 strain at two hour-time point with only spermine treatment, with only oxacillin and with
spermine and oxacillin in combination were compared with Mu50 two hour-time point without
spermine and oxacillin treatment. A significant stimulation of cell-wall-stress stimulon and
peptidoglycan synthesis genes with only spermine, or only oxacillin or with combination treatment
was not seen. Further analysis of sigB regulon, iron, potassium and polyamine transporter genes
status was performed. With only spermine and only oxacillin treatment, over 90 percent of genes
were found to be insignificant, while 45 percent of genes were found to be down regulated in
spermine with oxacillin treatment. This finding was overlapping with our previous finding where
there was down regulation of sigB regulon to high dose spermine stress [166]. We further saw the
induction of iron regulation genes with the spermine-oxacillin combination, while both potassium
and polyamine transport genes were found to be insignificant in all the conditions. Cell-wall-active
antibiotics can stimulate regulons controlled by RNA polymerase sigma factors. A cell-wall-stress
stimulon in Staphylococcus aureus has been reported by transcriptional profiling in response to
cell wall-active antibiotics. 98 genes upregulated by oxacillin treatment are noticed as a cell-wallstress stimulon in Staphylococcus aureus [192]. These genes are involved in several processes like
coenzyme metabolism, energy production, and conversion, lipid metabolism, secondary
metabolites biosynthesis, transport and catabolism, translation, ribosomal structure, and
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biogenesis. 29 such genes to be up-regulated with a fold change of greater than 1.5 with only
spermine treatment were identified. Most of these genes showed similar or higher up-regulation
with a spermine-oxacillin synergy at the one-hour time point. Genes potentially related to cell-wall
biosynthesis like murI (Glutamate racemase), murZ (UDP-N-acetylglucosamine 1-carboxylvinyl
transferase 2), PBP2, sgtB (Hypothetical protein like penicillin-binding protein 1A/1B) were not
seen to be significantly upregulated with spermine and spermine-oxacillin synergy. Oxacillin binds
to PBPs to inhibit the cross-linking step of peptidoglycan biosynthesis [192]. It has been proposed
that the cell responds to inhibition of peptidoglycan synthesis by increasing the transcription of the
pbpB gene to increase the rate of peptidoglycan synthesis [193]. MurZ is the first protein involved
in the biosynthesis of UDPN-acetylmuramyl pentapeptide [193]. We didn’t find a significant
stimulation of cell-wall-stress stimulon in Mu50 strain by only spermine treatment or with
spermine-oxacillin synergy as only 29 percent genes were significantly expressed. Also, we didn’t
see a significant stimulation of cell-wall biosynthesis genes with only spermine and with spermineoxacillin treatment, suggesting spermine alone or in combination with oxacillin can weaken cell
wall without stimulating genes in cell wall synthesis. When we compared Mu50 and MuM strains
with spermine and without oxacillin treatment, a general trend in down-regulation of cell structure
biosynthesis genes was seen in the Mu50 strain which was absent in MuM. The peptidoglycan
synthesis genes like bifunctional N-acetylglucosamine-1-phosphate, phosphoglucosamine
mutase, UDP-N-acetylglucosamine

2-epimerase,

phospho-N-acetylmuramic-pentapeptide-

transferase, UDP-N-acetylmuramoylalanine-D-glutamate ligase, UDP-N-acetyl muramate-Lalanine

ligase,

D-alanine-D-alanine

ligase,

and

UDP-N-acetylglucosamine

1-

carboxyvinyltransferase were down-regulated in Mu50 strain. Some of these genes seemed to be
down-regulated in MuM, but a general trend in down-regulation was consistent in Mu50 when
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compared to MuM. Lipid metabolism genes like NADPH-dependent glycerol-3-phosphate
dehydrogenase, phosphatidylglycerophosphate synthase, enoyl reductase, an acyl carrier protein,
3-oxoacyl-ACP synthase were seen to be down-regulated in Mu50 treated with spermine. It has
been proposed that spermine can form a complex with PBP2 protein eliciting conformational
change to weaken interactions among enzymes in the complex and inhibit the trans-glycosylase
activity of PBP2 in cell wall synthesis by increasing the transcription of the pbpB gene to increase
the rate of peptidoglycan synthesis [166]. Given our observations, it seems to contradict this
hypothesis as there is down-regulation of peptidoglycan synthesis genes in Mu50 on spermine
stress. Further analysis of these genes with real-time PCR can provide more insights on validating
these

observations.

5.3.1.6 Analysis of spermine-dependent synergy with beta-lactams on cell wall synthesis: The
synergy between spermine and oxacillin reduces the degree of cross-linkage on cell wall:

Peptidoglycan was digested with M1 muramidase, and the fragments were analyzed by HPLC to
determine the composition and degree of cell wall cross-linkage in spermine/oxacillin-grown cells.
As shown in Figure 19.1, there were no major changes seen in the biochemical composition of PG
in the presence of spermine (0.5mM) alone, oxacillin (1ng/µl) alone or their combination.
Figure 19 Chromatograms of peptidoglycan analysis by HPLC. Effect of Spm/betalactam on the muropeptide composition and degree of cross-linking of peptidoglycan extracted
from S. aureus Mu50.

93

However, we do saw diﬀerences in the degree of cross-linking between glycan chains within the
samples. The combination treatment results in a more depressed hump (retention time 110 minutes
and after) in this sample, while samples of spermine or oxacillin alone do not cause any significant
changes on the chromatograms (data not shown). Depressed humps on chromatogram have also
been encountered in Staphylococcus aureus at high doses of beta-lactams that block the
biochemical functions of PBPs [160]. Since PG cross-linking is catalyzed by PBPs, this result
suggests an enhanced PBP inactivation by oxacillin-spermine synergy. The PBPs contribution in
cell wall synthesis can be aﬀected by oxacillin/spermine synergy at multiple levels of transcription
and translation; the binding aﬃnity with beta-lactams; the enzymatic activity, which may result
from irregular conformation, incorrect localization, masked active sites, etc. To study if PBP2a or
the PBPs complex is involved in the synergism, we then tested if spermine suppresses PBP’s
expression; whether spermine enhances the PBPs-beta-lactam binding and whether spermine can
directly interact with PBPs to influence their activities. We did not evaluate whether spermine can
delocalize PBP(s) or prevent their recruitment to the septum due to some technical limitations.
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5.3.1.7 Transcriptional or translational expression of PBPs is not seen to be aﬀected by spermine
treatment:

We compared microarray gene expression levels of PBPs in MRSA Mu50 treated with spermine
(1mM), oxacillin (16ng/µl), or in combination. As seen in Figure 19.2 (signal intensities of
diﬀerent PBP expression), no significant diﬀerences were detected between untreated and treated
transcripts, suggesting low-dose spermine by itself or in combination with beta-lactams may not
aﬀect the PBP transcription. To examine whether spermine can influence the PBPs protein levels,
lysates from Mu50 grown in the presence of diﬀerent concentrations of spermine (0.5mM, 2mM,
10mM) were labeled to Bocillin labeling (for detection of PBP1-4) or Western blot (for detection
of PBP2a). Again, we didn’t see any significant changes in the quantities of any PBPs as seen in
Figure 19.3. Thus, we conclude that spermine may not aﬀect PBPs expression either at the
transcriptional or translational level. The PBP2 mutant strain MuM became spermine resistant and
showed no spermine/beta-lactam synergy which suggested that PBPs could be the target for
spermine. In line with this, the reduced PG crosslinking by a combination of low dose spermine
and oxacillin further supports the hypothesis of spermine perturbing cell wall integrity in favor of
beta-lactam eﬃcacy. However, a series of experiments investigating spermine eﬀects on PBPs, the
beta-lactam targets, implies that spermine does not appear to suppress the PBPs expression or alter
their interactions with beta-lactams. Besides, no apparent stimulation of cell-wall-stress stimulon
in Mu50 strain by only spermine treatment or with spermine-oxacillin synergy was observed (as
only 29 percent of cell wall stimulon genes were significantly expressed). Even so, these results
cannot rule out the possibility that the enzymatic activities of PBP-associated multi-enzyme
complexes might be modulated directly by binding of spermine to the complexes or indirectly
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through delocalization or reconfiguration of the complexes on the membrane. Also, spermine may
perturb other cell wall-related factors (instead of PBPs) to achieve the spermine/beta-lactam
synergy. Our unpublished data showing other spontaneous mutants with mutation not locating on
pbp2 also lose the synergy like MuM, suggest that other gene defects may confer similar impacts
as that of PBP2 deficiency in MuM to block the spermine target. Although we did not see the upregulation of cell wall stimulon by the spermine/oxacillin combination, the induced expression of
iron uptake genes in Mu50 strain drew our attention. Iron and H2O2 or its precursor superoxide
(O2-) are required for the Fenton reaction to generate destructive hydroxyl radicals (-OH), which
can trigger a common oxidative damage cellular death pathway by increasing the transcription of
the pbpB gene to increase the rate of peptidoglycan synthesis [193] [194]. Bactericidal antibiotics
including beta-lactams can trigger superoxide production through destabilization of the electron
transport chain and in our transcriptome data, iron/heme acquisition was highly stimulated by
spermine. Therefore, one possibility was that the enhanced ferrous iron uptake by spermine,
together with superoxide generated by beta-lactams significantly intensifies the Fenton reaction
and subsequently causes cell death. There is also a possibility of beta-lactams augmenting
spermine eﬀects during the synergy. The extensively aﬀected energy production pathways
(glycolysis, fermentation, TCA cycle) by spermine may also perturb the electron transport chain.
If so, one presumption is: beta-lactam inhibited cell wall synthesis will disturb membrane potential
which cooperates with the possible deficiency on the electron transport chain endowed by
spermine eﬀect to kill the bacteria. In conclusion, a significant down-regulation in an iron
regulatory system, potassium channel uptake and polyamine transport system with an upregulation in general stress response sigB dependent operon in MuM strain at 15, 30 and 60minutes time points with spermine treatment when compared to Mu50 is observed. The electron
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transfer chain, carbohydrate biosynthesis, cell structure fatty acid and lipid biosynthesis systems
were seen to be down-regulated in Mu50 and unaﬀected in MuM strain on spermine stress.
Furthermore, analysis of spermine-dependent synergy with beta-lactams on cell wall synthesis
revealed that it significantly reduces the degree of cross-linkage on cell wall with no change in
trypsin digestion patterns of purified PBPs and without aﬀecting PBPs expression or PBPs
acylation by Bocillin.

5.3.1.8 Spermine does not help in enhancing the binding of beta-lactams to PBPs:

To evaluate if spermine can enhance binding of beta-lactams to PBPs binding during
synergy, PBPs in Staphylococcus aureus lysate or purified PBPs were incubated with Bocillin
(fluorescent beta-lactam derivative) with or without spermine treatment. Lysates from Mu50
grown in the medium free of spermine or oxacillin were pre-incubated with 0.5mM spermine and
subjected to labeling by Bocillin of indicated concentrations. The binding aﬃnities were estimated
by measuring the fluorescence intensities of acylated PBPs by Bocillin. As illustrated in figure
19.4, the binding kinetics of Bocillin to PBPs were unaﬀected by the presence of spermine. We
then studied beta-lactam-PBP binding aﬃnity individually or in combination with purified PBPs.
As shown in Figure 19.5, we calculated aﬃnity of Bocillin for diﬀerent PBP’s through a
monophasic saturation curve. A notably higher dissociation constant (Kd) for PBP2a than those of
other PBPs and was consistent with its low aﬃnity to beta-lactams and the resultant high betalactam MIC for MRSA was seen. We also compared the individual Kd values between spermine
treated and untreated samples where no significant variations were detected. Coomassie staining
of the same gel ensured no variations in protein amount between samples (data not shown). Our
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results

suggest

that

spermine

may

not

aﬀect

PBP

acylation

by

beta-lactams.

5.3.1.9 Binding of spermine to PBPs does not cause conformational changes to PBPs, as tested
with trypsin digestion patterns:

Binding of spermine to PBPs may cause conformational changes causing sensitivity of
ligand-protein complexes against protease digestion. So, we utilized DARTS (drug aﬃnity
responsive target stability) method to look for possible conformation changes of PBPs due to
spermine interaction. Purified PBP was pre-incubated with or without spermine and subjected to
trypsin digestion following a time course with subsequent SDS-PAGE separation. The unrelated
carboxylesterase Est55 served as control. As shown in Figure 32.6, no significant diﬀerence on the
digestion patterns were observed regardless of spermine treatment.
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